Neutralization of acetyl-coa binding proteins conferring autophagy-dependent organ protection

CN118922206APending Publication Date: 2024-11-08INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +3
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202380023101.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-08
Filing Date
2023-02-07
Publication Date
2024-11-08

AI Technical Summary

Benefits of technology

[0009] The invention is defined by the claims. In particular, the present invention relates to methods and pharmaceutical compositions for protecting organs from injury (ie, treating or reducing tissue damage resulting from injury), including neutralization of acetyl-CoA binding proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure HDA0005005060800000011
    Figure HDA0005005060800000011
  • Figure HDA0005005060800000012
    Figure HDA0005005060800000012
  • Figure HDA0005005060800000021
    Figure HDA0005005060800000021
Patent Text Reader

Abstract

Serious consequences can be generated when important organs are injured, and even life is threatened. Organ injury has different causes, and generally includes drug, toxin and ischemic injury. Acetyl CoA Binding Protein (ACBP), also known as diazepam Binding Inhibitor (DBI), is an extracellular feedback modulator of autophagy. Here, the inventors report that injection of a monoclonal antibody (alpha-DBI) that neutralizes ACBP / DBI protects mouse liver from ischemia / reperfusion damage, acute poisoning of acetaminophen and concanavalin A, and liver fibrosis caused by ligation of biliary ducts or carbon tetrachloride. Notably, the result supports the viewpoint that alpha-DBI can mediate a wide range of organ protection against a variety of injuries. Thus, the present invention relates to methods and pharmaceutical compositions for protecting organs from injury, including neutralization of acetyl-CoA binding proteins.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross reference:

[0002] This application claims priority to European application serial number EP22305137 filed on February 8, 2022, the disclosure of which is incorporated herein by reference in its entirety. Technical field:

[0003] The present invention belongs to the field of medicine, in particular to the field of physiology. Background technology:

[0004] Injury to vital organs (such as, for example, the heart, brain, lungs, kidneys, gastrointestinal tract or liver) can have serious and even life-threatening consequences. Organ injury has different causes and generally includes drugs, toxins and ischemic injury. For example, studies on the cellular pathophysiology of ischemic injury in acute myocardial infarction have consistently shown that a large part of tissue damage occurs during reperfusion, i.e., the period of ischemia is greater than about ten minutes after the blood flow is restored. This injury is the cause of abnormal organ death and tissue damage after the end of the reperfusion period. IRI can be seen in almost all organ systems. The mechanisms involved in IRI include decreased high-energy phosphate (ATP) levels within a few hours after tissue ischemia, cellular and microvascular damage mediated by inflammatory cells (neutrophils), no reflow phenomenon (reperfusion deficiency), microvascular dysfunction caused by platelet blockage and endothelial damage during reperfusion, and tissue perfusion deficiency, and calcium overload-mediated reperfusion injury.

[0005] A common consequence of organ injury is fibrosis. Fibrosis is indeed the formation of fibrous connective tissue in response to injury. It is characterized by the accumulation of extracellular matrix components (particularly collagen) at the site of injury. Fibrosis is an adaptive response and an important component of wound healing and tissue repair. However, its continued activation is very harmful and is a common final pathway for a variety of disease states (including neurological, renal, cardiovascular, liver and respiratory diseases).

[0006] Therefore, there remains a need for therapies to protect organs from damage and thereby prevent subsequent fibrosis.

[0007] Macroautophagy (hereafter referred to as “autophagy”) is a process in which a portion of the cytoplasm is sequestered in an autophagosome, which subsequently fuses with a lysosome to enzymatically hydrolyze the autophagic cargo (Morishita and Mizushima, 2019). Although autophagy is often observed in the context of cell death, it primarily serves a cytoprotective function. Therefore, excessive autophagy leading to cell demise (“autophagic cell death” or “autosis”) is a rare phenomenon. In contrast, in most cases, cellular stress-induced autophagy delays or avoids cell death by promoting cellular adaptation (Kroemer and Levine, 2008; López-Otín and Kroemer, 2021; Schwartz, 2021). This stress-adaptive function of autophagy results from multiple factors, including but not limited to (i) mobilization of macromolecules, including proteins, mRNA, lipids, and glycogen, to generate energy-rich metabolites and building blocks for anabolic reactions, and (ii) selective removal of damaged cellular structures, including aggregates of misfolded proteins, uncoupled or permeabilized mitochondria, and other dysfunctional organelles (Galluzzi et al., 2014; López-Otín and Kroemer, 2021; Mizushima and Klionsky, 2007). Thus, cellular fitness is improved in a cell-autonomous manner. In addition, autophagy attenuates the activation of proinflammatory pathways due to the removal of molecules that may activate endogenous pattern recognition receptors (such as cytosolic DNA or reactive oxygen species) and due to the downregulation of downstream signals from such receptors (Deretic, 2021; Galluzzi et al., 2018; Schwartz, 2021). Given the widespread impact of autophagy, induction of autophagy has been proposed as a general strategy to combat disease.

[0008] Recently, an extracellular feedback loop of autophagy has been described and involves the protein acetyl-CoA binding protein (ACBP), which is called diazepam binding inhibitor (DBI) (Bravo-San Pedro et al., 2019a). In fact, autophagy is associated with the atypical secretion of this leaderless protein, which is mainly found in the cytoplasm of nucleated cells (Bravo-San Pedro et al., 2019a; Loomis et al., 2010). Once released into the extracellular space, ACBP / DBI then acts on gamma-aminobutyric acid (GABA) receptors to inhibit autophagy via autocrine, paracrine and neuroendocrine pathways (Bravo-San Pedro et al., 2019a; Joseph et al., 2020). When injected intraperitoneally or intravenously, a monoclonal antibody (mAb) against ACBP / DBI (referred to as α-DBI) significantly reduced high-fat diet-induced obesity, diabetes, and hepatic steatosis, while enhancing autophagy, lipolysis, and β-oxidation, while reducing appetite (Bravo-San Pedro et al., 2019a; Joseph et al., 2020, 2021). These effects are believed to be targeted because they can be mimicked by inducible systemic knockout of ACBP / DBI (Bravo-San Pedro et al., 2019a). Therefore, methods and pharmaceutical compositions for regulating autophagy based on modulating DBI activity or expression are disclosed (WO2019057742). Summary of the invention:

[0009] The invention is defined by the claims. In particular, the invention relates to methods and pharmaceutical compositions for protecting organs from injury (ie, treating or reducing tissue damage caused by injury) comprising neutralization of acetyl-CoA binding protein. Specific implementation method:

[0010] Acetyl-CoA binding protein (ACBP), also known as diazepam binding inhibitor (DBI), is an extracellular feedback regulator of autophagy. Here, the inventors report that injection of a monoclonal antibody (α-DBI) that neutralizes ACBP / DBI (in some embodiments, extracellular DBI) protects (i.e., treats or reduces morbidity) mouse livers from ischemia / reperfusion injury, acute poisoning with acetaminophen and concanavalin A, and from liver fibrosis caused by bile duct ligation or carbon tetrachloride. α-DBI administration down-regulated pro-inflammatory and pro-fibrotic genes and up-regulated antioxidant defenses and fatty acid oxidation in the liver. Notably, the results support the view that α-DBI can mediate a broad range of organ protective effects against a variety of injuries.

[0011] Main definitions:

[0012] As used herein, the terms "subject," "individual," or "patient" are used interchangeably and refer to any subject, particularly a human, for whom diagnosis, treatment, or therapy is desired. Other subjects may include cows, dogs, cats, guinea pigs, rabbits, rats, mice, horses, etc. In some preferred embodiments, the subject is a human.

[0013] As used herein, the term "organ" refers to a solid vascularized organ that performs a specific function or group of functions in an organism. The term organ includes, but is not limited to, the heart, lung, kidney, liver, pancreas, skin, uterus, bone, cartilage, small or large intestine, bladder, brain, breast, blood vessel, esophagus, fallopian tube, gallbladder, ovary, pancreas, prostate, placenta, spinal cord, limbs (including upper and lower limbs), spleen, stomach, testicles, thymus, thyroid, trachea, ureter, urethra, uterus.

[0014] As used herein, the term "organ dysfunction" means and includes a weakening or impairment of the physical structure or function of an organ.

[0015] As used herein, the term "solid organ transplant" and its variants refer to the insertion of a solid organ (also called a graft) into a recipient, whether the transplant is syngeneic (donor and recipient are genetically identical) or allogeneic (donor and recipient are of different genetic origin but belong to the same species).

[0016] As used herein, the term "injury" or "damage" refers to any damage that directly or indirectly affects normal function. Injuries may have a variety of causes, including but not limited to physiological damage, chemical damage, or physical damage. The terms cover acute injuries and chronic injuries. As used herein, the term "acute injury" includes injuries that occurred recently. For example, an acute injury may have occurred recently, may have occurred in an hour or less, may have occurred in a day or less, may have occurred in a week or less, or may have occurred in two weeks or less. As used herein, the term "chronic injury" is an injury that persists for a period of time. For example, a chronic injury may have occurred more than two weeks ago, may have occurred more than three weeks ago, may have occurred more than two months ago, or may have occurred more than three months ago.

[0017] As used herein, the term "ischemia" refers to a restricted blood supply, resulting in organ damage or dysfunction. Ischemia is not hypoxia (a more general term meaning a shortage of oxygen, usually caused by a lack of oxygen in the air you breathe), ischemia is an absolute or relative shortage of blood supply to an organ, i.e., a shortage of oxygen, glucose, and other blood-borne components. A relative shortage means that the blood supply (oxygen / fuel delivery) does not match the blood required for adequate metabolism of the tissue. As used herein, the term "warm ischemia" has the general meaning of the art and is used to describe ischemia of cells and tissues under normal temperature conditions. As used herein, the term "cold ischemia" has the general meaning of the art and refers to cooling of an organ during a period of reduced blood perfusion or the absence of a blood supply.

[0018] As used herein, the term "reperfusion" has its ordinary meaning in the art and refers to the restoration of blood flow to tissues after ischemia. Therefore, as used herein, the term "ischemia-reperfusion" or "I / R" is intended to cover events in which a reperfusion episode occurs after an ischemic episode.

[0019] As used herein, the term "ischemia-reperfusion injury" or "I / R injury" refers to tissue damage caused by an ischemia-reperfusion event. The absence of oxygen and nutrients in the blood during ischemia can lead to a situation in which restoration of circulation leads to inflammation and oxidative damage by inducing oxidative stress rather than (or accompanied by) restoration of normal function. As used herein, the term "ischemia-reperfusion injury severity" or "I / R injury severity" refers to a measure of the extent of injury.

[0020] As used herein, the term "fibrosis" refers to the formation of fibrous tissue as a repair or reactive process rather than as a normal component of an organ or tissue. Fibrosis is characterized by the accumulation of myofibroblasts and collagen deposition in excess of normal deposition in any particular tissue.

[0021] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably herein to refer to amino acid polymers of any length. These terms also encompass amino acid polymers that have been modified; for example, disulfide bond formation, glycosylation, lipidation, phosphorylation, or conjugation with a labeling component. The polypeptide discussed in the context of gene therapy refers to the corresponding intact polypeptide, or any fragment or genetically engineered derivative thereof that retains the desired biochemical function of the intact protein.

[0022] As used herein, the term "polynucleotide" refers to a polymeric form of nucleotides of any length, including deoxyribonucleotides or ribonucleotides or their analogs. A polynucleotide may contain modified nucleotides, such as methylated nucleotides and nucleotide analogs, and may be interspersed with non-nucleotide components. If present, the modification of the nucleotide structure may be performed before or after polymer assembly. As used herein, the term polynucleotide refers interchangeably to double-stranded molecules and single-stranded molecules. Unless otherwise specified or required, any embodiment of the invention as a polynucleotide described herein encompasses each of the double-stranded form and the two complementary single-stranded forms known or predicted to constitute the double-stranded form.

[0023] As used herein, the term "coding" refers to the inherent properties of a specific nucleotide sequence in a polynucleotide (such as, for example, a gene, cDNA or mRNA) used as a synthetic template for other polymers and macromolecules with a determined nucleotide sequence (e.g., rRNA, tRNA and mRNA) or a determined amino acid sequence in a biological process, and the biological properties resulting therefrom. Therefore, if the transcription and translation of the mRNA corresponding to a gene produces a protein in a cell or other biological system, the gene, cDNA or RNA encodes the protein. The coding strand (whose nucleotide sequence is identical to the mRNA sequence and is generally provided in a sequence table) and the non-coding strand (used as a template for transcription of a gene or cDNA) can both be referred to as encoding a protein or other product of the gene or cDNA. Unless otherwise indicated, "polynucleotide sequences encoding amino acid sequences" include all nucleotide sequences that are degenerate versions of each other and encode the same amino acid sequence. The phrase "polynucleotide sequence encoding a protein or RNA" may also include introns, as long as the nucleotide sequence encoding the protein may contain introns in some versions.

[0024] As used herein, the term "expression inhibitor" refers to a natural or synthetic compound that has the biological effect of inhibiting the expression of a polynucleotide.

[0025] As used herein, the term "DBI" has the general meaning in the art and refers to the diazepam binding inhibitor, acetyl-CoA binding protein, encoded by the DBI gene (Gene ID: 1622). The term is also referred to as EP; ACBP; ACBD1; and CCK-RP. An exemplary amino acid sequence of DBI is represented by SEQ ID NO: 1.

[0026] SEQ ID NO: 1> sp|P07108|ACBP_HUMAN acetyl-CoA binding protein OS=Homo sapiens OX=9606GN=DBIPE=1SV=2

[0027] MSQAEFEKAAEEVRHLKTKPSDEEMLFIYGHYKQATVGDINTER

[0028] PGMLDFTGKAKWDAWN

[0029] ELKGTSKEDAMKAYINKVEELKKKYGI

[0030] As used herein, the terms "antibody" and "immunoglobulin" have the same meaning and are used equally in the present invention. As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules containing antigen binding sites that immunospecifically bind to antigens. Therefore, the term antibody encompasses not only whole antibody molecules, but also antibody fragments and variants (including derivatives) of antibodies and antibody fragments. In natural antibodies, two heavy chains are connected to each other by disulfide bonds, and each heavy chain is connected to a light chain by a disulfide bond. There are two types of light chains: lambda (I) and kappa (k). There are five main heavy chain classes (or isotypes) that determine the functional activity of antibody molecules: IgM, IgD, IgG, IgA, and IgE. Each chain contains different sequence domains. The light chain includes two domains, a variable domain (VL) and a constant domain (CL). The heavy chain includes three (α, δ, γ) to five (μ, ε) domains, one variable domain (VH) and three to four constant domains (CH1, CH2, CH3 and CH4, collectively referred to as CH). The variable regions of the light chain (VL) and the heavy chain (VH) determine the binding recognition and specificity with the antigen. The constant region domains of the light chain (CL) and the heavy chain (CH) confer important biological properties, such as antibody chain association, secretion, transplacental mobility, complement binding, and binding to the Fc receptor (FcR). The Fv fragment is the N-terminal part of the Fab fragment of the immunoglobulin and is composed of the variable part of one light chain and one heavy chain. The specificity of the antibody lies in the structural complementarity between the antibody binding site and the antigenic determinant. The antibody binding site is composed of residues mainly from the hypervariable region or the complementary determining region (CDR). Sometimes, residues from non-hypervariable regions or framework regions (FR) can participate in the antibody binding site or affect the entire domain structure, thereby affecting the binding site. CDR refers to the amino acid sequence that jointly defines the binding affinity and specificity of the natural Fv region of the natural immunoglobulin binding site. The light chain and heavy chain of the immunoglobulin each have three CDRs, respectively named L-CDR1, L-CDR2, L-CDR3 and H-CDR1, H-CDR2, H-CDR3. Therefore, the antigen binding site generally includes six CDRs, which include a CDR group from each of the heavy and light chain V regions. The framework region (FR) refers to the amino acid sequence between the CDRs. The residues in the variable domain of the antibody are conventionally numbered according to the system designed by Kabat et al. The system is described in Kabat et al., 1987, in Sequences of Proteins of Immunological Interest, US Department of Health and Human Services, NIH, USA (hereinafter referred to as "Kabat et al."). This specification uses the numbering system.The names of Kabat residues do not always directly correspond to the linear numbering of amino acid residues in the SEQ ID sequence. The actual linear amino acid sequence may contain fewer or additional amino acids than the strict Kabat numbering, which corresponds to the shortening or insertion of the structural components of the basic variable domain structure (whether framework region or complementary determining region (CDR)). The correct Kabat residue numbering of a given antibody can be determined by comparing homologous residues in the antibody sequence with the "standard" Kabat numbering sequence. The CDRs of the heavy chain variable domain are located at residues 31-35B (H-CDR1), residues 50-65 (H-CDR2) and residues 95-102 (H-CDR3) according to the Kabat numbering system. The CDRs of the light chain variable domain are located at residues 24-34 (L-CDR1), residues 50-56 (L-CDR2) and residues 89-97 (L-CDR3) according to the Kabat numbering system.

[0031] As used herein, the terms "monoclonal antibody", "monoclonal Ab", "monoclonal antibody composition", "mAb" and the like refer to a preparation of antibody molecules of single molecular composition. A monoclonal antibody is obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies contained in the population are identical except for possible naturally occurring mutations that may be present in minor amounts.

[0032] As used herein, the term "chimeric antibody" refers to an antibody comprising the VH domain and VL domain of a non-human antibody and the CH domain and CL domain of a human antibody. In some embodiments, a "chimeric antibody" is an antibody molecule in which (a) the constant region (i.e., heavy chain and / or light chain) or a portion thereof is changed, replaced or exchanged so that the antigen binding site (variable region) is connected to a constant region of a different or changed class, effector function and / or species, or to a completely different molecule that imparts new properties to the chimeric antibody, such as an enzyme, toxin, hormone, growth factor, drug, etc.; or (b) the variable region or a portion thereof is changed, replaced or exchanged for a variable region with a different or changed antigen specificity. Chimeric antibodies also include primatized antibodies, particularly humanized antibodies. In addition, chimeric antibodies may contain residues that are not present in the recipient antibody or the donor antibody. These modifications are performed to further improve antibody performance. For further details, see Jones et al., Nature 321:522-525 (1986); Riechmann et al., Nature 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol. 2:593-596 (1992). (See U.S. Pat. No. 4,816,567; and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).

[0033] As used herein, the term "humanized antibody" refers to an antibody having a variable region framework and constant region from a human antibody but retaining the CDR of a previous non-human antibody. In some embodiments, a humanized antibody contains a minimal sequence derived from a non-human immunoglobulin. To a large extent, a humanized antibody and its antibody fragment can be a human immunoglobulin (receptor antibody or antibody fragment), wherein the residues of the complementary determining region (CDR) of the receptor are replaced by the residues of the CDR of a non-human species (donor antibody) (such as mouse, rat or rabbit) with desired specificity, affinity and ability. In some cases, the Fv framework region (FR) residues of a human immunoglobulin are replaced by corresponding non-human residues. In addition, a humanized antibody / antibody fragment can be included in a residue that does not exist in a receptor antibody or an imported CDR or framework sequence. Such antibodies are designed to maintain the binding specificity of the non-human antibody derived from the binding region, but avoid immune responses against non-human antibodies. These modifications can further improve and optimize the performance of an antibody or antibody fragment. In general, a humanized antibody or antibody fragment thereof will comprise substantially all of at least one and usually two variable domains, wherein all or substantially all of the CDR regions correspond to the CDR regions of a non-human immunoglobulin, and all or most of the FR regions are FR regions of human immunoglobulin sequences. A humanized antibody or antibody fragment may also comprise at least a portion of an immunoglobulin constant region (Fc), typically a constant region of a human immunoglobulin. For further details, see Jones et al., Nature, 321: 522-525, 1986; Reichmann et al., Nature, 332: 323-329, 1988; Presta, Curr. Op. Struct. Biol., 2: 593-596, 1992.

[0034] As used herein, the term "human antibody" is intended to include antibodies having variable regions and constant regions derived from human immunoglobulin sequences. The human antibodies of the present invention may include amino acid residues not encoded by human immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species (such as a mouse) have been transplanted onto human framework sequences.

[0035] As used herein, the term "antibody fragment" refers to at least a portion of an intact antibody, preferably an antigen binding region or variable region of an intact antibody, which retains the ability to specifically interact with an antigen epitope (e.g., by binding, steric hindrance, stabilization / destabilization, spatial distribution). A "fragment" includes a portion of an intact antibody, typically an antigen binding site or variable region. Examples of antibody fragments include Fab, Fab', Fab'-SH, F(ab')2, and Fv fragments; diabodies; any antibody fragment that is a polypeptide having a primary structure consisting of an uninterrupted sequence of consecutive amino acid residues (referred to herein as a "single-chain antibody fragment" or "single-chain polypeptide"), including but not limited to (1) a single-chain Fv molecule; (2) a single-chain polypeptide containing only one light chain variable domain, or a fragment thereof containing the three CDRs of a light chain variable domain without the associated heavy chain portion; and (3) a single-chain polypeptide containing only one heavy chain variable region, or a fragment thereof containing the three CDRs of a heavy chain variable region without the associated light chain portion; and multispecific antibodies formed by antibody fragments. Fragments of antibodies of the present invention can be obtained using standard methods.

[0036] As used herein, the term "specificity" refers to the ability of an antibody to detectably bind to a target molecule (e.g., an epitope presented on an antigen) while having relatively little detectable reactivity with other target molecules. Specificity can be relatively determined by binding or competitive binding assays, such as using a Biacore instrument as described elsewhere herein. Specificity can be manifested, for example, as a binding affinity / avidity ratio of a specific antigen to a nonspecific antigen binding to other unrelated molecules of about 10:1, about 20:1, about 50:1, about 100:1, about 10.000:1 or higher.

[0037] As used herein, the term "affinity" refers to the strength of the binding of an antibody to a target molecule (e.g., an epitope). The affinity of a binding protein is given by the dissociation constant Kd. For an antibody, the Kd is defined as [Ab] x [Ag] / [Ab-Ag], where [Ab-Ag] is the molar concentration of the antibody-antigen complex, [Ab] is the molar concentration of unbound antibody, and [Ag] is the molar concentration of unbound antigen. The affinity constant Ka is defined as 1 / Kd. Preferred methods for determining the affinity of a binding protein can be found in Harlow et al., Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988); Coligan et al., ed., Current Protocols in Immunology, Greene Publishing Assoc. and Wiley Interscience, NY, (1992, 1993); and Muller, Meth. Enzymol. 92: 589-601 (1983), which are incorporated herein by reference in their entirety. A preferred standard method for determining the affinity of a binding protein, well known in the art, is to use a Biacore instrument.

[0038] As used herein, the term "binding" refers to the direct association between two molecules due to, for example, covalent, electrostatic, hydrophobic, ionic and / or hydrogen bonding interactions (including interactions such as salt bridges and water bridges). Specifically, as used herein, in the context of antibody binding to a predetermined target molecule (e.g., an antigen or epitope), the term "binding" generally refers to an affinity corresponding to about 10 -7 M or less, such as about 10 -8 M or less, such as about 10 -9 M or lower, about 10 -10 M or lower, or about 10 -11 M or even lower K D combination.

[0039] As used herein, the term "neutralizing anti-DBI monoclonal antibody" refers to a monoclonal antibody that is specific for DBI and inhibits, reduces, or completely inhibits the activity of DBI (e.g., extracellular DBI). Whether an antibody is a neutralizing antibody can be determined by in vitro assays described in the examples. Typically, the neutralizing antibodies of the present invention inhibit the activity of DBI by at least 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100%.

[0040] As used herein, the term "treatment" or "treat" refers to prophylactic or preventive treatment and curative or disease-modifying treatment, including treatment of patients at risk of exposure to a disease or suspected of exposure to a disease and patients who are ill or have been diagnosed with a disease or medical illness, and includes suppression of clinical relapse. Treatment can be administered to patients with a medical condition or who may eventually develop the condition in order to prevent the condition or recurrent condition, cure the condition or recurrent condition, delay the onset of the condition or recurrent condition, alleviate the severity of the condition or recurrent condition, or improve one or more symptoms of the condition or recurrent condition, or to extend the patient's survival beyond the expected survival in the absence of such treatment. "Therapeutic regimen" means a mode of treating a disease, such as a mode of administration used during treatment. The therapeutic regimen may include an induction regimen and a maintenance regimen. The phrase "induction regimen" or "induction phase" refers to a therapeutic regimen (or a portion of a therapeutic regimen) for the initial treatment of a disease. The overall goal of an induction regimen is to provide a high level of drug to the patient in the initial phase of the therapeutic regimen. The induction regimen may employ (in part or in whole) a "loading regimen," which may include administering a larger dose of the drug than the physician would administer during a maintenance regimen, administering the drug more frequently than the physician would administer during a maintenance regimen, or both. The phrase "maintenance regimen" or "maintenance phase" refers to a treatment regimen (or portion of a treatment regimen) used to maintain a patient during treatment of a disease, e.g., to keep the patient in remission for an extended period of time (months or years). A maintenance regimen may employ continuous therapy (e.g., administration of the drug at fixed intervals, e.g., weekly, monthly, yearly, etc.) or intermittent therapy (e.g., interruption of treatment, intermittent treatment, treatment upon relapse, or treatment upon reaching specific predetermined criteria [e.g., pain, disease manifestations, etc.]).

[0041] As used herein, the term "pharmaceutical composition" refers to a composition described herein, or a pharmaceutically acceptable salt thereof, and other agents, such as a carrier and / or excipient. The pharmaceutical compositions provided herein typically include a pharmaceutically acceptable carrier.

[0042] As used herein, "consisting essentially of" when referring to a composition means that at least one antibody of the present invention as described above is the only therapeutic agent or biologically active agent in the composition.

[0043] As used herein, the term "pharmaceutically acceptable carrier" includes any and all solvents, diluents or other liquid vehicles, dispersion or suspension aids, surfactants, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, etc. suitable for the particular dosage form desired. Remington's Pharmaceutical-Sciences, 16th edition, EW Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers for formulating pharmaceutical compositions and known techniques for their preparation.

[0044] As used herein, the term "therapeutically effective amount" refers to an amount that effectively achieves the desired therapeutic result at a dosage and within a necessary time period. The therapeutically effective amount of an active agent may vary according to factors such as the disease state, age, sex and weight of the individual and the ability of the active agent to cause a desired response in the individual. The therapeutically effective amount is also the amount in which any toxic or harmful effects of the drug are offset by the therapeutic beneficial effects. The effective dose and dosage regimen of the active agent depend on the disease or illness to be treated and can be determined by those skilled in the art. A physician with ordinary skills in the art can easily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, the initial dose of the active agent used by the physician in the pharmaceutical composition can be lower than the level required to achieve the desired therapeutic effect, and the dose is gradually increased until the desired effect is achieved. Generally speaking, the appropriate dose of the composition of the present invention will be the amount of the compound, which is the minimum dose that effectively produces a therapeutic effect according to a specific dosage regimen. This effective dose will generally depend on the above factors. For example, the therapeutically effective amount for therapeutic use can be measured by its ability to stabilize disease progression. A person of ordinary skill in the art will be able to determine such amounts based on such factors, such as the size of the patient, the severity of the patient's symptoms, and the specific composition or route of administration selected. An exemplary, non-limiting range of a therapeutically effective amount of the drug of the present invention is about 0.1-100 mg / kg, such as about 0.1-50 mg / kg, for example about 0.1-20 mg / kg, such as about 0.1-10 mg / kg, for example about 0.5, about such as 0.3, about 1, about 3 mg / kg, about 5 mg / kg or about 8 mg / kg. An exemplary, non-limiting range of a therapeutically effective amount of the drug of the present invention is 0.02-100 mg / kg, such as about 0.02-30 mg / kg, such as about 0.05-10 mg / kg or 0.1-3 mg / kg, for example about 0.5-2 mg / kg.

[0045] Methods of conferring protection to organs:

[0046] The first object of the present invention relates to a method of conferring organ protection (i.e., treating or reducing tissue damage caused by injury) in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity or expression of DBI (e.g., circulating or extracellular DBI). Therefore, disclosed herein is a composition for treating or reducing tissue damage caused by the injury described herein in an organ of a subject, the composition comprising an amount of an agent that inhibits the activity or expression of a diazepam binding inhibitor (DBI), wherein when administered to a subject, the amount is sufficient to treat or reduce tissue damage caused by injury in an organ of the subject.

[0047] The methods and compositions of the present invention are particularly useful for preventing organ dysfunction.

[0048] The methods and compositions of the present invention are particularly suitable for conferring organ protection against any type of injury. In some embodiments, the methods or compositions of the present invention are particularly suitable for conferring organ protection against chemical injury (treating or reducing tissue damage caused by chemical injury). In some embodiments, the methods or compositions of the present invention are particularly suitable for conferring organ protection against physical injury (treating or reducing tissue damage caused by physical injury). In some embodiments, the methods or compositions of the present invention are particularly suitable for conferring organ protection against ischemic injury (treating or reducing tissue damage caused by ischemic injury).

[0049] In particular, the methods or compositions of the present invention are particularly useful for conferring organ protection against (treating or reducing tissue damage caused by) chemical injury induced by a toxicant selected from the group consisting of alcohol, 2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB-153), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-bromoethylamine (BEA), 3-methylcholanthrene, 4-aminophenol (PAP), acetaminophen, adriamicin, allyl alcohol, amiodarone, amphotericin B, Aroclor 1254, Aroclor 1260, arsenic, aspirin, astemizole, benzene, cadmium, carbamazepine, carbon tetrachloride (CCl4), ciprofibrate (cipro), clofibrate, cobalt chloride, corvastatin, cyclosporin A (cyclosporin A), diethylnitramine, dimethylformamide, dimethylhydrazine (DMH), diquat, ethosuximide, etoposide, famotidine, fluconazole, gamfibrozil, ganciclovir, hexachloro-1,3-butadiene (HCBD), HIV protease inhibitors, hydrazine, indomethacin, ketoconazole, lead acetate (PbAc), lipopolysaccharide (LPS), mercury (II) chloride (HgCl2), methanol, methapyrilene, methotrexate, metronidazole ), miconazole, monocrotaline, nitric oxide, ondansetron, pentamidine, phenobarbital, phenylhyrzn, phenytoin, pravastatin, propulsid, puromycin aminonucleoside (PAN), quinolones, simvastatin, sodium fluoride (NaF), statins, thioacetamide, tocainidine, tricyclic antidepressants, troglitazone, tumor necrosis factor α (TNFα), uranyl nitrate, valproic acid, vincristine, Wy-16,463, zidovudine (AZT), α-naphthyl isothiocyanate (ANIT), β-naphthoflavone (BNF), asbestos, radon, cigarette smoke, glue, dioxins, nickel, arsenic, mercury, cement (chromium), polychlorinated biphenyls (PCBs), carbon tetrachloride, methylene chloride, vinyl chloride, mercury, chlorinated hydrocarbon solvents, carbon disulfide, cadmium, ozone, tobacco smoke, nitrates, methylene chloride, vinyl dibromide, and polychlorinated biphenyls.

[0050] In some embodiments, the methods or compositions of the invention are particularly useful for conferring organ protection against (treating or reducing tissue damage caused by) chemotherapeutic agents. Chemotherapeutic agents include, but are not limited to, alkylating agents such as thiotepa and cyclosphosphamide; alkylsulfonates such as busulfan, improsulfan, and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines, including altretamine, triethylenemelamine, triethylenephosphoramide, triethiylenethiophosphoramide, and trihydroxymethylmelamine. imethylolomelamine; acetogenins (especially bullatacin and bullatacinone); camptothecins (including the synthetic analog topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin, and in) and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; sarcodictyin; spongistatin;Nitrogen mustards, such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard, mustard; nitrosureas, such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine and ranimnustine; antibiotics, such as the enediyne antibiotics (e.g., calicheamicins, especially calicheamicin gamma ll and calicheamicin omega ll; dynemicins, including dynemicin A; bisphosphonates, such as clodronate; esperamicins; and the neocarcinogen chromophores and related chromoprotein enediyne antibiotic chromophores, aclacinomycins, actinomycins ( ctinomycin), authrarnycin, azaserine, bleomycin, cactinomycin, carabicin, caminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholinodoxorubicin, cyanomorpholinodoxorubicin, 2-pyrrolodoxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin;Mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercindin, ubenimex, zinostatin, zorubicin; antimetabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pterin, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopyrimidine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, propionate, epitiostanol, mepitiostane, testolactone; antiadrenal agents such as aminoglutethimide, mitotane, trilostane; folic acid supplements such as frolinic acid; aceglatone; aldophosphamide glycosides; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; epothilone; etoglucid;Gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids, such as maytansine and ansamitocin; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid acid; 2-ethylhydrazide; procarbazine; PSK polysaccharide complex; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid acid; triaziquone; 2,2′,2″-trichlorotriethylamine; trichothecenes (particularly T-2 toxin, verracurin A, roridin A, and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; cytarabine (“Ara-C”); cyclophosphamide; thiiotepa; taxanes , for example, paclitaxel and docetaxel; chloranbucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum coordination complexes, such as cisplatin, oxaliplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine; novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeloda; ibandronate; irinotecan (e.g., CPT-1 1); the topoisomerase inhibitor RFS2000;difluoromethylornithine (DMFO); retinoids, such as retinoic acid; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the foregoing. ;

[0051] In some embodiments, the methods or compositions of the present invention are particularly useful for conferring organ protection against drug-induced injury induced by anthracyclines (treating or reducing tissue damage caused by drug-induced injury induced by anthracyclines), wherein the anthracycline is selected from the group consisting of: daunorubicin, doxorubicin, epirubicin, famorubicin, idarubicin, mitoxantrone, and pixantrone; and pharmaceutically acceptable salts thereof.

[0052] In some embodiments, the methods or compositions of the invention are particularly useful for treating acetaminophen-induced hepatotoxicity, amiodarone-induced pulmonary toxicity, doxorubicin-induced cardiotoxicity, cadmium chloride-induced nephrotoxicity, dimethylnitrosamine-induced splenoretoxicity, and O-ethyl-S,S-dipropyl dithiophosphate (MOCAP)-induced neurotoxicity.

[0053] The method or composition of the present invention can be applied to any ischemic injury or event. Tissues particularly susceptible to ischemic events include myocardium, blood vessels and neural tissue (particularly brain tissue). Other tissues susceptible to ischemia include tissues of the intestine, liver, kidney and eyes. For example, due to certain physiological conditions during trauma or cardiac arrest, such as unstable angina, cardioprotection may be required. In addition, conditions such as stroke, transient ischemic attack or impending stroke (transient blackout) are also candidate diseases for treatment using the method of the present invention. When a stroke causing a risk of secondary stroke occurs, or other diseases causing a risk of stroke occur within hours or days, the method can be applied to reduce this risk. Those skilled in the art will recognize situations associated with increased risk of other ischemic tissue damage. Such disease states include mesenteric artery insufficiency, renal artery stenosis, hepatic vein thrombosis, peripheral vascular insufficiency, multiple trauma, sepsis and multiple organ system failure. Other ischemic events include angiographic evidence of partial coronary artery occlusion, echocardiographic evidence of myocardial damage, or any other evidence of future or additional ischemic event risk (e.g., myocardial ischemic events, such as myocardial infarction (MI), or neurovascular ischemia, such as cerebrovascular accident CVA). Ischemia / reperfusion may damage tissues other than myocardial tissue. The methods or compositions provided herein are particularly suitable for reducing ischemia-reperfusion injuries that may occur in the brain, liver, intestines, kidneys, intestinal tissues, or any other tissues. Additional applications include blunt or penetrating trauma that causes blood flow interruption to internal organs, including abdominal penetrating injuries caused by gunshot wounds, stabbing wounds, or blood flow interruption caused by penetrating injuries or blunt abdominal trauma caused by deceleration injuries and / or motor vehicle accidents. Other preferred applications include diseases or procedures that cause systemic hypotension, which can destroy or reduce blood flow to internal organs, including hemorrhagic shock caused by blood loss, cardiogenic shock caused by myocardial infarction or heart failure, neurogenic shock, or anaphylaxis.

[0054] In some embodiments, the use of the methods or compositions of the present invention can improve organ protection during surgical procedures that require stopping the blood supply to an organ and then reperfusing it. Examples of surgical procedures that generate a risk of ischemia-reperfusion injury include liver resection; revascularization after myocardial infarction, such as by thrombolytic therapy, stent implantation, or surgical repair; revascularization after stroke, such as by thrombolytic therapy or surgical repair; or revascularization after vascular injury, including limb repair or reconnection after ischemic injury or surgical repair of aneurysms. Other examples are upper or lower gastrointestinal surgery, including laparoscopic surgery, open-chest surgery with or without a heart-lung machine, nose and throat surgery, vascular surgery, neurological (brain) surgery, transplantation (liver, heart, lung, kidney, intestine), liver surgery, and cesarean section. In some embodiments, the surgical procedure is coronary artery bypass surgery, also known as coronary artery bypass graft (CABG) surgery or heart bypass surgery or just bypass surgery, which is a surgical procedure performed to relieve angina and reduce the risk of dying from coronary artery disease. Arteries or veins from other parts of the patient's body are transplanted to the coronary arteries to bypass atherosclerotic stenosis and improve the blood supply of the coronary circulation that supplies the myocardium (heart muscle). This operation is usually performed when the heart stops beating, requiring the use of cardiopulmonary bypass; there is currently technology that can perform CABG on a beating heart, the so-called "off-pump" operation. In some embodiments, the method of the present invention can be used in any surgical procedure that requires clamping the blood supply of an organ. Specifically, the method of the present invention is applied to all surgical procedures involving the connection of two blood vessels, such as coronary artery bypass surgery, peripheral bypass surgery, hemodialysis access (establishing fistulas) and free flap surgery (breast and facial reconstruction surgery). More specifically, the method or composition of the present invention can be applied to any surgical procedure that requires anastomosis. As used herein, the term "anastomosis" refers to a surgical connection between tubular structures (such as blood vessels).

[0055] Generally, an effective amount of an agent that inhibits the activity or expression of DBI (eg, extracellular DBI) can be administered to a patient before, during, or after reperfusion. Specifically, an effective amount of an agent that inhibits the activity or expression of DBI is administered to a patient during organ reperfusion.

[0056] In some embodiments, the method or composition of the present invention is particularly suitable for preventing the progression to chronic kidney disease (CKD) after acute kidney injury (AKI). As used herein, the term "chronic kidney disease" (CKD) refers to the progressive loss of renal function within months or years. CKD has the general meaning of this area, and is used to classify the various diseases affecting kidney, the destruction of renal parenchyma and the loss of functional nephron or glomerulus. It should be further noted that CKD may be caused by different reasons, but the final approach is still renal fibrosis. The term "acute kidney injury" or "acute renal failure" generally refers to the rapid deterioration of renal function, which is enough to cause the accumulation of nitrogenous waste in the body (see, for example, Anderson and Schrier (1994), in Harrison's Principles of Internal Medicine, the 13th edition, Isselbacher et al., McGrawHill Text, New York). The typical symptoms of acute renal failure are that the rate of increase of BUN is at least 4 to 8mmol / L / day (10 to 20mg / dL / day), and the rate of increase of serum creatinine is at least 40 to 80μmolΙ / L / day (0.5 to 1.0mg / dL / day). The urine sample of the patient suffering from acute renal injury may also contain renal tubular injury residue. In the subject of catabolism (or excessive catabolism), the rate of increase of BUN may exceed 100 / mg / dL / day. The rate of increase of BUN or serum creatinine can be determined by a series of blood tests, and at least two blood tests are preferably performed in the time period between 6 to 72 hours or more preferably in the time period between 12 to 24 hours. Sometimes "acute" renal failure (deterioration in a few days) and "rapidly progressing" renal failure (deterioration in a few weeks) are distinguished. However, as used herein, the phrase "acute renal injury" is intended to cover these two syndromes. As discussed above, acute renal injury is often found by clinicians. AKI may be caused by vascular abnormalities, such as vasoconstrictive disorders (e.g., malignant hypertension, scleroderma, hemolytic uremic syndrome, thrombotic thrombocytopenic purpura) and vasculitides (e.g., polyarteritis nodosa, hypersensitivity vasculitis, serum sickness, Wegener's granulomatosis, giant cell arteritis, mixed cryoglobulinemia, Henoch-Schonlein purpura, systemic lupus erythematosus).AKI may also result from glomerular abnormalities, such as postinfectious abnormalities (e.g., streptococcal, pneumococcal, gonococcal, staphylococcal, enterococcal, viral [e.g., hepatitis B and C, mumps, measles, Epstein-Barr], malaria, or associated with brucellosis, Legionella, Listeria, shunt nephritis, leprosy, leptospirosis, or visceral abscesses) and noninfectious abnormalities (e.g., rapidly progressive glomerulonephritis, membranoproliferative glomerulonephritis, Goodpasture's syndrome, systemic lupus erythematosus, Wegener's granulomatosis). In some embodiments, AKI may be caused by acute interstitial nephritis caused by drug-related causes (e.g., penicillins, sulfonamides, carbenicillin, cephalosporins, erythromycin, nafcillin, oxacillin, nonsteroidal anti-inflammatory drugs, diuretics (furosemide, ethacrynic acid, thiazides, spironolactone, mercurial preparations), phenytoin, phenobarbital, probenicid, allopurinol, cimetidine), infection-related causes (e.g., acute pyelonephritis, streptococci, staphylococci, leptospirosis, malaria, salmonellosis), papillary necrosis (e.g., associated with diabetes, sickle cell disease, analgesic abuse, alcoholism), and other miscellaneous causes (e.g., sarcoidosis, leukemia, lymphoma). In some embodiments, AKI may be caused by intratubular obstruction due to crystal deposition (e.g., uric acid, oxalate, methotrexate) or multiple myeloma and light chain disease. In some embodiments, AKI may be caused by acute tubular necrosis caused by nephrotoxins (e.g., antimicrobials such as aminoglycosides, tetracyclines, amphotericin, polymyxin, cephalosporins), heavy metals (e.g., mercury, lead, arsenic, gold salts, barium) and other various chemical agents (e.g., cisplatin, doxorubicin, streptozocin, methoxyflurane, halothane, ethylene glycol, carbon tetrachloride) or ischemia (e.g., hemorrhage, hypotension, sepsis, burns, renal infarction, renal artery dissection, rhabdomyolysis, trauma) or other various causes (e.g., contrast media, transfusion reactions, myoglobinemia, heat stroke, snake and spider bites).

[0057] The methods or compositions of the present invention are particularly suitable for preventing organ damage, reducing the severity of organ damage, or reducing the risk of organ damage. In some embodiments, the organ is isolated. In some embodiments, the organ is a transplant organ or a transplantable organ.

[0058] In some embodiments, the methods or compositions of the present invention can improve organ transplantation by administering to an isolated (transplanted) organ an effective amount of an agent that inhibits the activity or expression of DBI (e.g., extracellular DBI). Thus, in some embodiments, the organ will be transplanted into a recipient. Thus, the method is performed ex vivo in an isolated organ.

[0059] In some embodiments, the transplanted organ is a cadaveric organ, and in those cases where the organ is obtained from a cadaveric donor, an agent that inhibits DBI activity or expression can be administered to the cadaver or extracted organ. In some embodiments, the transplanted organ is a living organ donation, and in those cases, an agent that inhibits DBI activity or expression can be administered to the extracted organ.

[0060] In some embodiments, the organ is isolated and perfused with an effective amount of an agent that inhibits the activity or expression of DBI (eg, extracellular DBI).

[0061] In some embodiments, the transplanted organ is a subject of warm ischemia and / or cold ischemia.

[0062] In some embodiments, an effective amount of an agent that inhibits the activity or expression of DBI (e.g., extracellular DBI) is administered during the cold ischemic time. As used herein, the term "cold ischemic time" or "CIT" has the general meaning of the art and refers to the time from the start of cold storage of the recovered organ to the restoration of thermal circulation after transplantation. There are differences in the characteristics of the receiving surgeon / center and the donor and recipient. Intuitively, the shorter the CIT, the better. For kidney transplantation, CIT should be less than 24 hours; for pancreatic transplantation, CIT should be less than 18 hours, and for liver transplantation, CIT should be less than 8 hours (Bernat JL, D'Alessandro AM, Port FK, Bleck TP, Heard SO, Medina J et al. Report of a National Conference on Donation after cardiacdeath. Am J Transplant. 2006; 6: 281–91).

[0063] Ways to prevent fibrosis:

[0064] The methods or compositions of the invention are also particularly useful for preventing or reducing fibrosis associated with or following organ damage.

[0065] In some embodiments, fibrosis affects at least one organ selected from the group consisting of skin, heart, liver, lung or kidney. Examples of fibrosis include, but are not limited to, dermal scarring, keloids, liver fibrosis, lung fibrosis, kidney fibrosis, glomerulosclerosis, lung fibrosis (e.g., idiopathic pulmonary fibrosis), liver fibrosis, kidney fibrosis, intestinal fibrosis, interstitial fibrosis, pancreatic and lung fibrosis, injection fibrosis, endomyocardial fibrosis, mediastinal fibrosis, myelofibrosis, retroperitoneal fibrosis, progressive massive fibrosis, nephrogenic systemic fibrosis ... In some embodiments, fibrosis is caused by surgical implantation of an artificial organ.

[0066] For example, liver (liver) fibrosis occurs as part of the wound healing response of chronic liver damage. This damage may be the result of viral activity (for example, chronic hepatitis B or C) or other infections (for example, parasites, bacteria), chemicals (for example, drugs, alcohol, pollutants), immune processes (for example, autoimmune hepatitis), metabolic disorders (for example, lipid, glycogen or metal accumulation disease) or cancer growth. Liver fibrosis is characterized by extracellular matrix accumulation, which can be qualitatively distinguished from the extracellular matrix accumulation in normal liver. If not controlled, liver fibrosis can develop into cirrhosis (defined by the presence of encapsulated nodules), liver failure and death. As described herein, the method or composition can provide enough amount to reduce the transaminase level in the subject (compared with the transaminase level in the subject before application) when applying. In some embodiments, the transaminase is aspartate transaminase (AST) or alanine transaminase (ALT). As described herein, the method or composition can provide enough amount to reduce the fibrosis score by at least 1 / 3 (equivalent to the fibrosis score before application). Methods or compositions as described herein can provide sufficient amounts to reduce hydroxyproline levels in a subject when administered (compared to hydroxyproline levels in the subject before administration). Methods or compositions as described herein can provide sufficient amounts to reduce NAFLD scores in a subject when administered (equivalent to NAFLD scores before administration).

[0067] Renal fibrotic disorders include, but are not limited to, glomerulonephritis (including membranoproliferative, diffuse proliferative, rapidly progressive, post-infectious, and chronic forms), diabetic glomerulosclerosis, focal glomerulosclerosis, diabetic nephropathy, lupus nephritis, tubulointerstitial fibrosis, membranous nephropathy, amyloidosis (affecting the kidney and other tissues), renal arteriosclerosis, nephrotic syndrome, renal interstitial fibrosis, renal fibrosis in patients receiving cyclosporine, and HIV-associated nephropathy. The glomerulus is the primary target of many types of renal injury, including immune injury (e.g., immune complex-mediated or T-cell-mediated), hemodynamic injury (systemic or renal hypertension), metabolic injury (e.g., diabetes), "atherosclerotic injury" (accumulation of lipids in the glomerulus), infiltrative injury (e.g., amyloid), and toxic injury (e.g., snake venom). Renal structural changes in patients with diabetic nephropathy include glomerular hypertrophy, thickening of the glomerular and tubular membranes (due to matrix accumulation), and increased amounts of matrix in the mesangium and tubulointerstitium. Glomerular hypertension due to altered intrarenal hemodynamics in diabetes may contribute to the progression of diabetic nephropathy. Autoimmune nephritis can also lead to changes in the growth response of mesangial cells. Hepatitis C virus infection can also lead to idiopathic membranoproliferative glomerulonephritis.

[0068] Pulmonary fibrosis conditions include, but are not limited to, silicosis, asbestosis, idiopathic pulmonary fibrosis, bronchiolitis obliterans with organizing pneumonia, pulmonary fibrosis associated with high-dose chemotherapy, idiopathic pulmonary fibrosis, and pulmonary hypertension. These diseases are characterized by increased cell proliferation and production of extracellular matrix components such as collagen, elastin, fibronectin, and tenascin-C. The methods of the invention can also be used to treat subjects with asthma and other lung disorders associated with airway remodeling.

[0069] Pancreatic fibrosis occurs in chronic pancreatitis. The disease is characterized by calcification of the pancreatic ducts and fibrosis of the pancreatic parenchyma. Like cirrhosis, chronic pancreatitis is also associated with alcohol abuse.

[0070] The methods of the invention are also useful for treating intestinal fibrosis, particularly fibrosis associated with inflammatory bowel disease (eg, Crohn's disease and ulcerative colitis).

[0071] Skin fibrotic disorders that can be treated by the methods of the present invention include, but are not limited to, scleroderma, morphea, keloids, hypertrophic scars, familial cutaneous collagenomas, and collagenous connective tissue nevi. In addition, the methods of the present invention are useful for inhibiting excessive scarring in patients known to form keloid or hypertrophic scars, inhibiting or preventing scarring or excessive scarring during healing of various types of wounds, including surgical incisions, abdominal surgical wounds, and traumatic lacerations, preventing or inhibiting scarring and arterial reclosure after coronary angioplasty, and preventing or inhibiting excess scar or fibrous tissue formation associated with cardiac fibrosis in post-infarction and allergic vascular disease.

[0072] Ocular fibrotic disorders include disorders such as diabetic retinopathy, post-operative scarring (eg, after glaucoma filtration surgery and after strabismus surgery), and proliferative vitreoretinopathy.

[0073] Bone fibroproliferative disorders are characterized by abnormal and ectopic bone formation, often manifested by active proliferation of the major cell types involved in bone formation and processing of the complex bone matrix by these cells. An example of such a bone disorder is the fibrosis that occurs when prostate tumors metastasize to the axial skeleton. In cancellous bone growth associated with prostate tumors, prostate cancer cells can interact with osteoblasts when depositing in the bone to produce enhanced tumor growth and osteogenesis. Bone fibroproliferative reactions originating from the bone itself include osteosclerosis and osteophytes. Defects in osteoblast differentiation and function are considered to be the main cause of osteosclerosis, an inherited disorder characterized by bone sclerosis due to reduced bone resorption, failure of the bone marrow cavity to develop, resulting in extramedullary hematopoiesis and severe hematological abnormalities associated with optic atrophy, fibrous connection defects and intellectual disability. In osteoarthritis, bone changes are known to occur, and collagen metabolism is increased within the osteoarthritic femoral head. The greatest changes occur in the subchondral region, which supports a greater proportion of osteoid in the diseased tissue.

[0074] Vascular fibroproliferative disorders include, for example, transplant vasculopathy, which is the leading cause of chronic rejection of cardiac transplants. Transplant vasculopathy is characterized by accelerated atherosclerotic plaque formation with diffuse occlusion of the coronary arteries and is a typical fibroproliferative disease.

[0075] Additional fibrotic disorders that may be treated by the methods of the invention include rheumatoid arthritis, diseases associated with long-term joint pain and joint degeneration, progressive systemic sclerosis, polymyositis, dermatomyositis, eosinophilic fasciitis, morphea, Raynaud's syndrome, and nasal polyps.

[0076] In some embodiments, the methods of the present invention are particularly suitable for treating inflammation-induced fibrosis. As used herein, the expression "inflammation-induced fibrosis" refers to fibrosis that develops during or as a consequence of an inflammatory disease (i.e., a disease associated with acute or chronic inflammation (caused by tissue damage, pathogen infection, or toxic agents)).

[0077] In some embodiments, the methods of the invention are particularly useful for treating liver fibrosis.

[0078] The agent of the present invention:

[0079] In some embodiments, the agent that inhibits the activity of DBI (eg, extracellular DBI) is an antibody against DBI.

[0080] In some embodiments, the antibody is directed against a fragment (ie, an octapeptide or OP) comprising the amino acid sequence from amino acid residue at position 43 to amino acid residue at position 50 in SEQ ID NO: 1.

[0081] In some embodiments, the antibodies of the invention are chimeric antibodies, typically chimeric mouse / human antibodies.

[0082] In some embodiments, the antibody is a humanized antibody.

[0083] In some embodiments, the antibody is a human antibody. Fully human monoclonal antibodies can also be prepared by immunizing transgenic mice that contain a large number of human immunoglobulin heavy chain and light chain loci. See, e.g., U.S. Patent Nos. 5,591,669, 5,598,369, 5,545,806, 5,545,807, 6,150,584, and references cited therein, the contents of which are incorporated herein by reference.

[0084] In some embodiments, the antibody is a neutralizing antibody.

[0085] In some embodiments, the neutralizing antibodies of the present invention do not mediate antibody-dependent cell-mediated cytotoxicity, and therefore do not include an Fc portion that induces antibody-dependent cellular cytotoxicity (ADCC). In some embodiments, the neutralizing antibodies do not include an Fc domain that can substantially bind to FcgRIIIA (CD16) polypeptides. In some embodiments, the neutralizing antibodies lack an Fc domain (e.g., lack CH2 and / or CH3 domains) or comprise an Fc domain of an IgG2 or IgG4 isotype. In some embodiments, the neutralizing antibodies include Fab, Fab', Fab'-SH, F(ab')2, Fv, double antibodies, single-chain antibody fragments, or multispecific antibodies comprising multiple different antibody fragments or are composed thereof. In some embodiments, the neutralizing antibodies are not connected to toxic moieties. In some embodiments, one or more amino acids selected from amino acid residues may be replaced with different amino acid residues so that the antibody has a changed C2q binding and / or reduced or eliminated complement-dependent cytotoxicity (CDC). Idusogie et al. further describe the method in detail in U.S. Patent No. 6,194,551.

[0086] Several anti-DBI antibodies that inhibit the activity of DBI (eg, extracellular DBI) are suitable for use in the methods and compositions described herein. Such anti-DBI antibodies are commercially available and described in the literature. For example, an antibody that inhibits DBI (e.g., extracellular DBI) activity has at least 80%, at least 85%, at least 90%, at least 95%, or 100% sequence identity to the polypeptide sequence of an antibody selected from the group consisting of b231910 (rabbit polyclonal, abcam), ab232760 (rabbit polyclonal, abcam), ab16871 (rabbit polyclonal, abcam), sc-30190 (rabbit polyclonal, Santa Cruz Biotechnology), FNab02256 (rabbit polyclonal, Wuhan Fine Biotech Co), PA5-89139 (rabbit polyclonal, Invitrogen), OTI4A8 (mouse polyclonal, OriGene), OTI6E12 (mouse polyclonal, OriGene), or mAb 7A (mouse polyclonal, Fred Hutch Antibody Technology).

[0087] In some embodiments, the agent that inhibits the activity of DBI (e.g., extracellular DBI) is an aptamer for DBI. Aptamers are a class of molecules that can replace antibodies in molecular recognition. Aptamers are oligonucleotide sequences that can recognize almost any class of target molecules with high affinity and specificity. Such ligands can be isolated by systematic evolution of ligands by exponential enrichment (SELEX) of random sequence libraries. Random sequence libraries can be obtained by DNA combinatorial chemical synthesis. In this library, each member is a linear oligomer that is ultimately chemically modified to have a unique sequence. Peptide aptamers are composed of conformationally constrained antibody variable regions displayed by platform proteins (such as Escherichia coli thioredoxin A) and are selected from combinatorial libraries by two hybrid methods (Colas et al., 1996).

[0088] In some embodiments, the agent that inhibits DBI expression is an inhibitor of expression. In a preferred embodiment of the present invention, the inhibitor of gene expression is siRNA, endonuclease, antisense oligonucleotide or ribozyme.

[0089] In some embodiments, the agent that inhibits the activity of DBI (e.g., extracellular DBI) includes a vaccine composition suitable for inducing neutralizing autoantibodies against DBI when administered to a subject. For the purposes of the present invention, the term "vaccine composition" is intended to mean a composition that can be administered to a human or animal to induce an immune system response; the immune system response can result in the production of antibodies against DBI. Typically, the vaccine composition comprises at least one antigen derived from DBI. As used herein, the term "antigen" refers to a molecule that can be specifically bound by an antibody or T cell receptor (TCR) (if processed and presented by an MHC molecule). As used herein, the term "antigen" also encompasses T cell epitopes. Antigens can also be recognized by the immune system and / or can induce a humoral immune response and / or a cellular immune response, resulting in the activation of B lymphocytes and / or T lymphocytes. The antigen can have one or more epitopes or antigenic sites (B epitopes and T epitopes). In some embodiments, the antigen consists of a polypeptide comprising an amino acid sequence having at least 80% identity to a sequence of SEQ ID NO: 1 or a fragment thereof (e.g., an epitope). In some embodiments, the antigen consists of a polypeptide comprising i) an amino acid sequence having at least 80% identity with SEQ ID NO: 1, or ii) an amino acid sequence having at least 80% identity with the amino acid sequence from the amino acid residue at position 17 to the amino acid residue at position 50 in SEQ ID NO: 1, or iii) an amino acid sequence having at least 80% identity with the amino acid sequence from the amino acid residue at position 33 to the amino acid residue at position 50 in SEQ ID NO: 1, or iv) an amino acid sequence having at least 80% identity with the amino acid sequence from the amino acid residue at position 43 to the amino acid residue at position 50 in SEQ ID NO: 1. In some embodiments, the polypeptide is conjugated to a carrier protein, which is generally foreign enough to elicit a strong immune response to the vaccine. Exemplary carrier proteins are highly immunogenic in nature. When using animals for experiments, bovine serum albumin (BSA) and keyhole limpet hemocyanin (KLH) are commonly used as carriers for conjugate vaccine development, and are also considered herein as carrier proteins. Proteins used to prepare therapeutic conjugate vaccines include, but are not limited to, a variety of pathogenic bacterial toxins and their toxoids.Suitable carrier molecules are numerous and include, but are not limited to: bacterial toxins or products, such as cholera toxin B- (CTB), diphtheria toxin, tetanus toxoid, pertussis toxin and filamentous hemagglutinin, shigatoxin, pseudomonas exotoxin; lectins, such as ricin-B subunit, abrin and sweet pea agglutinin; subviral vectors, such as retroviral nucleoprotein (retro NP), rabies ribonucleoprotein (rabies RNP), plant viruses (e.g., TMV, cowpea and cauliflower mosaic virus), vesicular stomatitis virus-nucleocapsid protein (VSV-N), poxvirus vectors and Semliki forest virus (Semliki forest virus). virus) carrier; artificial carriers, such as multiple antigen peptides (MAP), microspheres; yeast virus-like particles (VLP); malarial protein antigens; and other substances, such as proteins and peptides, and any modifications, derivatives or analogs of the above substances. Other useful carriers include carriers with the ability to enhance mucosal response, more specifically, LTB family bacterial toxins, retroviral nucleoproteins (retro NP), rabies ribonucleoproteins (rabies RNP), vesicular stomatitis virus-nucleocapsid protein (VSV-N) and recombinant poxvirus subunits.

[0090] Drug composition:

[0091] Typically, agents that inhibit the activity or expression of DBI (e.g., extracellular DBI) are administered to patients in the form of pharmaceutical compositions comprising a pharmaceutically acceptable carrier. Pharmaceutically acceptable carriers that can be used for these compositions include, but are not limited to, ion exchangers, aluminum oxide, aluminum stearate, lecithin, serum proteins (such as human serum albumin), buffer substances (such as phosphates), glycine, sorbic acid, potassium sorbate, saturated vegetable fatty acids, mixtures of partial glycerides of water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, silica gel, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and lanolin. For use in administering to patients, the composition is formulated for administration to patients. The composition of the present invention can be administered orally, parenterally, by atomization inhalation, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. Parenteral as used herein includes subcutaneous, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. The sterile injectable form of the composition of this aspect can be an aqueous or oily suspension. These suspensions can be prepared using suitable dispersants or wetting agents and suspending agents according to techniques known in the art. Sterile injectable preparations can also be sterile injectable solutions or suspensions in non-toxic parenteral acceptable diluents or solvents, such as solutions in 1,3-butanediol. In acceptable vehicles and solvents, water, Ringer's solution (Ringer'ssolution) and isotonic sodium chloride solution can be used. In addition, sterile, fixed oils are generally used as solvents or suspension media. For this purpose, any mild fixed oil can be used, including synthetic monoglycerides or diglycerides. Fatty acids (such as oleic acid and its glyceride derivatives) can be used to prepare injections, such as natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated forms. These oil solutions or suspensions may also contain long-chain alcohol diluents or dispersants, such as carboxymethyl cellulose or similar dispersants commonly used to prepare pharmaceutically acceptable dosage forms (including emulsions and suspensions). Other commonly used surfactants, such as Tween, Span and other emulsifiers or bioavailability enhancers commonly used to make pharmaceutically acceptable solids, liquids or other dosage forms may also be used for formulation purposes. The composition of the present invention can be orally administered in any orally acceptable dosage form, including but not limited to capsules, tablets, aqueous suspensions or solutions. For tablets for oral use, commonly used carriers include lactose and corn starch. Lubricants, such as magnesium stearate, are also commonly added. For oral administration in capsule form, useful diluents include, for example, lactose. When an aqueous suspension is required for oral use, an agent that inhibits DBI activity or expression is combined with an emulsifier and a suspending agent. If desired, certain sweetening, flavoring or coloring agents may be added.Alternatively, the composition of the present invention can be used in the form of a suppository for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient, which is solid at room temperature but liquid at rectal temperature, and will therefore melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycol. The composition of the present invention can also be applied topically, especially when the treatment target includes an area or organ (including diseases of the eye, skin or lower intestinal tract) that is easily accessible by topical application. For each of these areas or organs, it is easy to prepare a suitable topical preparation. For topical application, the composition can be formulated into a suitable ointment containing an active component suspended or dissolved in one or more carriers. The carrier for topical application of the compounds of the present invention includes but is not limited to mineral oil, liquid vaseline, white vaseline, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water. Alternatively, the composition can be formulated into a suitable lotion or cream containing an active component suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitol monostearate, polysorbate 60, cetyl ester wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water. Topical application of the lower intestinal tract can be achieved with rectal suppository formulations (see above) or with suitable enema formulations. Patches can also be used. The compositions of the present invention can also be applied by nasal aerosol or inhalant. Such compositions are prepared according to well-known technology in the field of pharmaceutical formulations, and such compositions can be prepared into solutions in normal saline using benzyl alcohol or other suitable preservatives, absorption promoters that enhance bioavailability, fluorocarbons and / or other conventional solubilizing agents or dispersants.

[0092] In some embodiments, an agent that inhibits the activity or expression of DBI (e.g., extracellular DBI) of the present invention is directly administered to a subject or an isolated organ using an injection, a pump device, and / or any machine (e.g., a bypass machine). In some embodiments, an isolated organ suitable for transplantation is perfused with a preservation solution containing an effective amount of an agent that inhibits the activity or expression of DBI. As used herein, the term "preservation solution" or "organ preservation solution" refers to an aqueous solution with a pH between 6.5 and 7.5, including salts, preferably chloride, sulfate, sodium, calcium, magnesium, and potassium; sugars, preferably mannitol, raffinose, sucrose, glucose, fructose, lactobionate (which is waterproof) or gluconate; antioxidants, such as glutathione; active agents, such as xanthine oxidase inhibitors, such as allopurinol, lactate, amino acids, such as histidine, glutamic acid (or glutamate), tryptophan; and optional colloids, such as hydroxyethyl starch, polyethylene glycol, or dextran. In some embodiments, a device for preserving an organ is used, wherein the device comprises an organ container containing a preservation solution, characterized in that the device also includes one or more devices for injecting one or more compounds (e.g., agents that inhibit DBI activity or expression) into the organ container.

[0093] The present invention is further illustrated by the following figures and examples. However, these examples and figures should not be interpreted as limiting the scope of the present invention in any way. Description of the drawings:

[0094] Figure 1. Neutralization of ACBP / DBI activates autophagic flux and reduces organ damage in vivo. Liver injury produced by AC ischemia / reperfusion (IR) 90 minutes / 4 hours. Mice were pretreated with intraperitoneal injection of α-DBI or IgG (2.5μg / g) and HCQ (50mg / kg) for 4 hours before IR. Liver injury was assessed by histological examination (A). ALT (B) and AST transaminase activity (C) in plasma were analyzed by colorimetric assay (n=5-11 mice per group).

[0095] Figure 2. α-DBI alleviates organ toxicity induced by acetaminophen and Concanavalin A in mice. Damage induced by acetaminophen (APAP, ip 300 mg / kg, for 16 hours) or Concanavalin A (ConA, iv 12 mg / kg, for 4 hours) in mice pretreated for 4 hours with intraperitoneal injection of α-DBI or IgG (2.5 μg / g) and HCQ (50 mg / kg) before liver injury.

[0096] AC. Hepatoprotective effect of DBI neutralization after APAP intoxication. Liver damage (A) was measured by histological examination, taking into account the area of ​​cell death, degeneration (ballooning) and inflammation around central veins. ALT and AST transaminase activities in plasma mice (B and C) (n = 4-11 mice per group).

[0097] DF. Liver protection against ConA damage by DBI neutralization. Liver damage (D) was scored using the grade of infiltration and hepatocellular necrosis. ALT and AST transaminase (E and F) activities in plasma (n=3-11 mice per group).

[0098] Figure 3. ACBP / DBI neutralizes chronic injury-induced fibrosis. AC.C57BL / 6 mice received bile duct ligation (BDL) for 2 weeks. Mice were injected intraperitoneally with 2.5 μg / g IgG or α-DBI 4 hours and 1 hour before BDL, and fibrosis scores (A), ALT activity (B) and bilirubin levels (C) were measured twice a week during BDL (n = 5-10 mice per group). DE.C57BL / 6 mice were injected intraperitoneally with 2.5 μg / g α-DBI or IgG weekly, and 1.6 ml / kg CCl4 was injected intraperitoneally twice a week for 9 weeks. In the last 4 weeks of CCl4, additional groups were treated with 50 mg / kg / day of HCQ. Quantification of fibrosis stage (D) and plasma ALT (E) is shown in the figure (n = 5-14 mice per group).

[0099] Figure 4. ACBP / DBI neutralization alleviates hepatic steatosis induced by a methionine-choline deficient diet. AD. Male mice aged 2-3 months were fed with a regular chow diet (RCD) or a methionine-choline deficient diet (MCD) for 4 weeks. Hepatic F4 / 80 macrophages (A), NAFLD activity score (B), ALT and AST activities (C), and p62 levels (D) were measured.

[0100] Figure 5. ACBP / DBI neutralization alleviates hepatic steatosis induced by Western diet. AB. Male mice aged 2-3 months were fed with regular chow diet (RCD) or high-fat Western diet with sugar for 4 weeks. NAFLD activity score (A) and ALT and AST activities (B) were measured.

[0101] Figure 6. ACBP / DBI neutralization alleviates hepatic steatosis induced by Western diet and CCl4. AB. Male mice aged 2-3 months were fed with regular chow diet (RCD) or high-fat Western diet plus CCl4 for 4 weeks. NAFLD activity score (A) and ALT and AST activities (B) were measured.

[0102] Figure 7 ACBP / DBI neutralization alleviates fibrosis induced by Western diet and CCl4. C57BL / 6 mice were fed with a regular chow diet (RCD) or a high-fat Western diet plus sugar plus CCl4 for 4 weeks. Mice were injected intraperitoneally with 2.5 μg / g α-DBI or IgG weekly and 1.6 ml / kg CCl4 twice a week for 9 weeks. Quantification of fibrosis scores is shown (n=5-14 mice per group).

[0103] Figure 8. ACBP / DBI neutralization reverses fibrosis induced by CCl4. Mice received CCl4 for 9 weeks and then treated with vehicle (oil) for a 4-week reversal period (R). 2.5 μg / g IgG or α-DBI was injected intraperitoneally 1 day before reversal and once a week during the reversal period. Quantification of fibrosis stage (A), plasma ALT activity (B) and hydroxyproline levels (C) were measured (n = 4-12 mice per group).

[0104] Example 1: Materials and methods:

[0105] Chemicals and reagents

[0106] Reagents were obtained from xon Medchem BV (Groningen, Netherlands), Qiagen (Hilden, Germany), Millipore (MA, USA), Randox (Antrim, UK), Roche Applied Science (Upper Bavaria, Germany), and Sigma Aldrich (MO, USA). Electrophoresis reagents were obtained from Thermo Fisher Scientific (MA, USA) and BioRad (CA, USA). Antibodies were obtained from Abcam (TX, USA), Abnova (Taipei, China), Cell Signaling (MA, USA), and Sigma Aldrich.

[0107] Animal experiments

[0108] Wild-type (Wt) C57BL / 6 mice (Envigo, Gannat, France), homozygous Atg4b - / - Mice (gift from Dr.Carlos Lopez-Otin, University of Oviedo, Spain), tamoxifen-induced whole-body knockout of floxed Acbp / Dbi - / - Mouse (UBC-cre / ERT2::Acbp / Dbi fl / fl ,Control: Acbp / Dbi without CREfl / fl )(Bravo-SanPedro et al., 2019a), homozygous Gabrg2 mut / mut Mice (carrying a point mutation F77I in the ACBP / DBI binding site of the γ2 subunit of the γ-aminobutyric acid A receptor) (Wulff et al., 2007) and transgenic mice expressing LC3 conjugated to green fluorescent protein (GFP-LC3-Tg) (Mizushima et al., 2004) were bred and maintained according to the FELASA guidelines and the local guidelines of the Animal Experimentation Ethics Committee (license numbers 25000, 31411, 34537, 34538 and 34539). Mice were housed in a temperature-controlled environment with a 12-hour light / dark cycle and were fed food and water ad libitum. All animals were sacrificed, organs were snap-frozen in liquid nitrogen and stored at -80°C, or fixed overnight in 4% buffered paraformaldehyde at 4°C and embedded in paraffin. Plasma was obtained by cardiac puncture.

[0109] Neutralization of DBI by passive or active immunization

[0110] Anti-DBI monoclonal antibody (passive immunization) or isotype IgG (Bioxcell, NH, USA) was used in vivo in a single dose or several doses (2.5 μg / g body weight, BW, intraperitoneal, ip, in 200 μL). In some experiments, leupeptin (Leu, 30 mg / kg body weight) was injected intraperitoneally 2 hours before the end of the experiment.

[0111] As described by Montégut et al. (Montégut et al., 2022), the production of autoantibodies (active immunity) was induced by conjugating keyhole limpet hemocyanin (KLH; from Thermo) and mouse recACBP (KLH-DBI). Briefly, KLH and DBI were mixed at a molar ratio of 1:20 and gradually adjusted to 0.25% (vol / vol) glutaraldehyde. Afterwards, glycine solution was added to complete the reaction and ultrafiltration was performed using a 100 KDa membrane (Millipore). Formaldehyde solution was added to a final concentration of 0.2% (vol / vol), the reaction was quenched by adding glycine solution, and then ultrafiltration was performed with 70 mM pH 7.8 phosphate buffer. Eight-week-old male C57BL / 6 mice were immunized by intraperitoneal injection of 30, 30, 30, 10 μg of KLH-DBI or KLH alone as an adjuvant emulsion (1:1) with Montanide ISA-51vg (Seppic, Paris, France) on days 0, 7, 14, and 21, respectively.

[0112] Acute liver damage in mice

[0113] To induce hepatic ischemia-reperfusion injury, 12-week-old male C57BL / 6 mice were anesthetized with 2% isoflurane, and the segmental (70%) warm liver I / R protocol model was evaluated. et al., 2019). Briefly, hepatic ischemia was induced for 90 min, and reperfusion was initiated for 4 h by removing the clamps. To induce hepatotoxicity, 12-week-old male C57BL / 6 mice were treated with 12 mg / kg concanavalin A (ConA, Sigma Aldrich) or 300 mg / kg acetaminophen (APAP, SigmaAldrich) for 4 h or 16 h, respectively. To inhibit autophagic flux, animals were injected intraperitoneally with two doses of 50 mg / kg hydroxychloroquine (HCQ in PBS; AxonMedchem BV) 4 h before the onset of liver damage.

[0114] In vivo liver fibrosis model

[0115] To induce liver fibrosis, 2-month-old male C57BL / 6 mice were injected intraperitoneally with CCl4 (SigmaAldrich) at a dose of 1.6 ml / kg twice a week for 9 weeks. et al., 2016). Control animals were injected intraperitoneally with vehicle olive oil (Sigma Aldrich). During the last four weeks of CCl4, additional groups were injected intraperitoneally with 50 mg / kg HCQ daily. Another method of inducing liver fibrosis involves bile duct ligation (BDL) for 2 weeks (Tag et al., 2015).

[0116] Biochemical assays

[0117] Serum ALT and AST activities were determined by colorimetric kits (Randox) according to the manufacturer's instructions. To quantify collagen, liver hydroxyproline content was determined by a commercial kit (Sigma Aldrich).

[0118] Histopathology

[0119] Paraffin-embedded sections (5 μm) were stained with hematoxylin-eosin-saffron (HES) or Sirius red and evaluated by an experienced pathologist who was blinded to the characteristics of the animal groups. All slides were scanned with AxioScan Z1 (Carl Zeiss, Jena, Germany). The NAFLD activity score was assessed using the mouse model NAFLD scoring system validated by Liang et al. (Liang et al., 2014). Briefly, the steatosis grade was grouped as follows: grade 0, <5% steatotic hepatocytes; grade 1, 5–33%; grade 2, 33–66%; and grade 3, >66%. The hepatic lobular inflammation score was as follows: 0, no lesions; 1, <2 lesions; 2, 2–4 lesions; 3, >4 lesions. Ballooning degeneration was classified as follows: 0, no balloon cells; 1, a few balloon cells; 2, many balloon cells. The NAFLD activity score for each liver biopsy was calculated based on the sum of the scores for steatosis, inflammation, and ballooning. In addition, the liver fibrosis stage (Metavir score) was defined as: 0, no fibrosis; 1, perisinusoidal and / or pericentral; 2, incomplete central / central bridging fibrosis; 3, complete central / central bridging fibrosis; and 4, definite cirrhosis (Bedossa and Poynard, 1996). The severity of liver IR was graded from 0 to 4 according to the Suzuki criteria. No (0%), minimal (10%), mild (11-30%), moderate (30-60%), and severe (>60%) necrosis, congestion, or ballooning of the liver lobule were assigned grades 0, 1, 2, 3, and 4, respectively (Suzuki et al., 1993). To measure APAP hepatotoxicity, liver samples were classified as none (0; 0%), mild (1; less than 20%), moderate (2; 20-70%), and severe (3; more than 70% of liver lobules) considering the area of ​​cell death, ballooning degeneration, and inflammation around central veins (Naiki-Ito et al., 2010). ConA-induced liver injury was scored using the following scale: 0, no necrotic infiltration; 1, small patches of necrotic cells between hepatocytes or necrotic cells around a single hepatocyte; 2, larger patches of 100 necrotic cells or involving 30 hepatocytes; 3, 10% of the liver cross section was involved; 4, 30% of the liver cross section was involved (Zhao et al., 2020). In addition, to determine the abundance of hepatic macrophages and Kupffer cells, immunohistochemical staining of liver sections fixed in paraffin blocks was performed using anti-mouse F4 / 80 according to standard procedures.

[0120] Liver Extract

[0121] For protein or RNA extraction, tissues were homogenized using a Precellys 24 tissue homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) at 5,500 rpm for 2 cycles for 20 sec in 20 mM Tris buffer (pH 7.4) containing 150 mM NaCl, 1% Triton X-100, 10 mM EDTA, and Protease inhibitor cocktail (Roche Applied Science) or QIAzol (Qiagen). Afterwards, the protein extract was centrifuged at 12,000g (4°C) for 15 min, and the supernatant was collected. The protein concentration in the supernatant was evaluated by bicinchoninic acid technique (BCA protein assay kit, Thermo Fisher Scientific). Homogenized RNA was purified using RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. TM RNA purification and concentration were measured (Thermo Fisher Scientific).

[0122] Data analysis

[0123] Data are expressed as mean ± SEM. For statistical analysis, first, the normal distribution of the results was evaluated by D'Agostino & Pearson normality test and Shapiro-Wilk normality. Statistical significance was analyzed using Student's unpaired two-tailed t-test or unpaired two-tailed Mann-Whitney test to assess the differences between treated and untreated mice within a single genotype and between genotypes. The analysis was performed using the statistical software GraphPad Prism 5. Whole transcriptome sequencing and GEO data set statistical analysis were tested by Fisher's exact test. For statistical analysis of metabolomics, p values ​​were calculated by Mann-Whitney test. All target processing data were merged and cleaned using a dedicated R (version 3.4) package (@Github / Kroemerlab / GRMeta). p<0.05 was considered statistically significant.

[0124] Example 2: Organ protective effects of ACBP / DBI neutralization against acute injury.

[0125] Injection of a monoclonal antibody (mAb) (α-DBI) neutralizing ACBP / DBI (2.5 μg / g intraperitoneally, ip, 6 hours and 2 hours before sacrifice) enhanced hepatic lipidation of microtubule-associated protein 1A / 1B light chain 3B (hereinafter referred to as LC3B), a marker of autophagy, resulting in a more electrophoretically mobile LC3-II form (data not shown) (Mizushima et al., 2004). This effect was further enhanced by injection of the lysosomal protease inhibitor leupeptin (30 mg / kg ip 2 hours before sacrifice), confirming an increase in autophagic flux (Haspel et al., 2011) (data not shown). Thus, a single injection of α-DBI (2.5 μg / gi.p. 4 hours before sacrifice) induced the formation of autophagic puncta in mouse hepatocytes expressing a transgene encoding a green fluorescent protein (GFP)-LC3 fusion protein (Mizushima et al., 2004) (data not shown). Two injections of α-DBI also reduced histological signs of liver ischemia / reperfusion (congestion, ballooning, and necrosis summarized in the Suzuki score) (Suzuki et al., 1993) ( Figure 1A ), and increased plasma concentrations of two transaminases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ( Figure 1B 、 Figure 1C When α-DBI injection was combined with hydroxychloroquine (50 mg / kg), a lysosomal chemoattractant that inhibits autophagy in vivo (Cook et al., 2014), the liver protection effect of ACBP / DBI neutralization against ischemia / reperfusion was lost ( Figure 1A-Figure 1C In two pharmacological hepatotoxicity models induced by acetaminophen (APAP, trade name: paracetamol) and lectin concanavalin A (ConA), a similar hydroxychloroquine-inhibitory hepatoprotective effect of α-DBI was obtained ( Figure 2 In both models, α-DBI reduced histological signs of liver injury as well as circulating transaminase levels ( Figure 2 ).

[0126] Example 3: ACBP / DBI neutralization inhibits fibrosis.

[0127] We used a model of liver fibrosis induced by bile duct ligation (BLD) (Brea et al., 2018). Two weeks after BLD, liver damage and fibrosis were evident in mice treated with isotype control antibodies but were greatly alleviated after biweekly injections of α-DBI ( Figure 3A -Figure C). Similar results were obtained using a well-established model of carbon tetrachloride (CCl4)-induced liver fibrosis conditioned by weekly administration of α-DBI (or isotype IgG control for 9 weeks) and / or daily injections of hydroxychloroquine (or vehicle control during the last 4 weeks of the experiment). In this model, α-DBI reduced weight loss, signs of fibrosis detectable by Sirius red staining ( Figure 3D ), or quantification of the collagen-rich amino acid hydroxyproline (data not shown), and liver damage as reflected by transaminase activity ( Figure 3E ), as well as liver damage reflected by immunoblotting of profibrotic markers collagen 1A1 and α-smooth muscle actin (α-SMA) (data not shown). When hydroxychloroquine inhibited autophagy, the beneficial effects of α-DBI on liver damage and fibrosis were lost ( Figure 3D 、 Figure 3E ). CCl4-induced changes in p62 and LC3-II were reversed by α-DBI, but only in the absence of hydroxychloroquine and not in its presence (data not shown). α-DBI also reversed CCl4-induced increases in circulating aminotransferases, again only in the absence of hydroxychloroquine ( Figure 3E ). In addition, α-DBI reversed most (if not all) transcriptional effects of chronic CCl4 poisoning, thereby reducing the expression of profibrotic genes, proinflammatory genes, macrophage-related genes, or transforming growth factor-β (TGF-β)-related genes, but enhancing the expression of antioxidant enzymes. When hydroxychloroquine was administered simultaneously, these transcriptional effects of α-DBI were eliminated (data not shown). In a further set of experiments, we determined whether CCl4-induced liver fibrosis could be more effectively reversed when CCl4 withdrawal was combined with weekly injections of α-DBI for 4 weeks (data not shown). Similarly, in this treatment setting, α-DBI reduced signs of liver fibrosis (data not shown). In summary, these data show that ACBP / DBI neutralization has a beneficial effect on liver fibrosis, which is largely dependent on autophagy.

[0128] Example 4: ACBP / DBI reduces diet-induced hepatic steatosis

[0129] Diet-induced hepatic steatosis was used to model the treatment of nonalcoholic fatty liver disease (NAFLD). First, the effects of ACBP / DBI neutralization on a NASH model occurring in the context of weight loss, which was induced by a methionine-choline deficient diet (MCD) (control: regular chow diet (RCD)). After 4 weeks of MCD, NASH features were evaluated in mice that received weekly injections of α-DBI (control: isotype immunoglobulin G [IgG] mAb). α-DBI reduced NASH-associated inflammation, as measured by a reduction in F4 / 80 macrophages in the liver ( Figure 4A ) and largely prevented histological signs (as determined by the NAFLD activity score, measured as the sum of steatosis, inflammation, and ballooning— Figure 4B ) and enzymatic signs of MCD-induced NASH (ALT and AST) ( Figure 4C ). Furthermore, α-DBI reversed the inhibition of autophagic flux associated with NASH, as evidenced by a decrease in the autophagic substrate p62 in mice receiving α-DBI relative to controls.

[0130] Next, the effects of ACBP / DBI neutralization on a NASH model developed in subjects consuming a high-fat Western diet were determined. After 4 weeks of Western diet, NASH features were evaluated in mice that received weekly injections of α-DBI (control: isotype immunoglobulin G [IgG] mAb). In addition, another group of mice that received a Western diet were administered CCl4 intraperitoneally to induce fibrosis. As with MCD-induced NASH, α-DBI largely prevented histological signs of Western diet-induced NASH (determined by the NAFLD activity score— Figure 5A ) and enzyme signs (ALT and AST) ( Figure 5B ). In addition, in mice fed a Western diet and administered CCl4, α-DBI administration reduced the NAFLD activity score of NASH ( Fig. 6A ) and enzyme signs (ALT and AST— Figure 6B ). Furthermore, α-DBI administration reduced fibrosis associated with CCl4 administration in mice fed a Western diet, as evidenced by a decrease in fibrosis scores ( Figure 7 ).

[0131] Finally, the ability of α-DBI to reverse CCl4-induced liver fibrosis was determined. To induce liver fibrosis, 2-month-old male C57BL / 6 mice were injected intraperitoneally with CCl4 (Sigma Aldrich) at a dose of 1.6 ml / kg twice a week for 9 weeks, followed by a 4-week reversal period (R) with vehicle (oil). 2.5 μg / g IgG or α-DBI was injected intraperitoneally 1 day before the reversal period, and once a week during the reversal period. Control animals were injected intraperitoneally with vehicle olive oil (SigmaAldrich). Again, in this treatment setting, α-DBI reduced signs of damage to liver fibrosis, as evidenced by a decrease in fibrosis scores ( Fig. 8A )、ALT activity( Figure 8B ) and hydroxyproline content ( Figure 8C ) to determine.

[0132] In summary, ACBP / DBI neutralization via α-DBI reduced NASH-associated hepatic steatosis and liver fibrosis in multiple models and could even reverse liver fibrosis after development, thus further demonstrating the therapeutic potential of ACBP / DBI neutralization via α-DBI.

[0133] References:

[0134] Throughout this application, various references describe the state of the art to which the invention pertains. The disclosures of these references are hereby incorporated by reference into this disclosure.

[0135] Allaire, M., Rautou, PE, Codogno, P., and Lotersztajn, S. (2019). Autophagyin liver diseases: Time for translation? Journal of Hepatology 70,985-998.

[0136] Aman, Y., Schmauck-Medina, T., Hansen, M., Morimoto, RI, Simon, AK, Bjedov, I., Palikaras, K., Simonsen, A., Johansen, T., Tavernarakis, N., et al. (2021). Autophagy in healthy aging and disease. Nature Aging 1, 634-650.

[0137] Ashcroft, T., Simpson, JM, and Timbrell, V. (1988). Simple method of estimating severity of pulmonary fibrosis on a numerical scale. Journal of Clinical Pathology 41,467.

[0138] Bedossa,P., and Poynard,T.(1996).An algorithm for the grading ofactivity in chronic hepatitis C.Hepatology 24,289-293.

[0139] Bejarano,L.,Jordāo,M.J.C.,and Joyce,J.A.(2021).Therapeutic Targetingof the Tumor Microenvironment.Cancer Discovery 11,933-959.

[0140] Bravo-San Pedro,J.M.,Sica,V.,Martins,I.,Pol,J.,Loos,F.,Maiuri,M.C.,Durand,S.,Bossut,N.,Aprahamian,F.,Anagnostopoulos,G.,et al.(2019a).Acyl-CoA-Binding Protein Is a Lipogenic Factor that Triggers Food Intake andObesity.Cell Metabolism 30,754-767.e9.

[0141] Bravo-San Pedro,J.M.,Sica,V.,Martins,I.,Anagnostopoulos,G.,Maiuri,C.,and Kroemer,G.(2019b).Cell-autonomous,paracrine and neuroendocrine feedbackregulation of autophagy by DBI / ACBP(diazepam binding inhibitor,acyl-CoAbinding protein):the obesity factor.Autophagy15,2036-2038.

[0142] Brea,R., O.,French,D.,Garcia-Monzon,C.,Vargas,J.,Fernandez-Velasco,M.,Bosca,L.,Casado,M.,Martin-Sanz,P.,and Agra,N bydownregulating miR-23a-5p and miR-28a-5p.Biochemistry and Biophysics Acta(BBA)-Molecular Basis of Disease 1864,325-337.

[0143] Capurro, MI, Greenfield, LK, Prashar, A., Xia, S., Abdullah, M., Wong, H., Zhong, XZ.,Bertaux-Skeirik, N., Chakrabarti, J., Siddiqui, I., et al eliminated by activation of the lysosomal calcium channel TRPML1.NatureMicrobiology 4,1411-1423.

[0144] Chao,X.,and Ding,WX(2019).Role and mechanisms of autophagy in alcohol-induced liver injury.Advances in Pharmacology(San Diego,Calif.)85,109-131.

[0145] Charmpilas,N.,Ruckenstuhl,C.,Sica,V.,Büttner,S.,Habernig,L.,Dichtinger,S.,Madeo,F.,Tavernarakis,N.,Bravo-San Pedro,J.M.,and Kroemer,G.(2020).Acy1-CoA-binding protein(ACBP):a phylogenetically conserved appetitestimulator.Cell Death&Disease 11.

[0146] Chiang,W.C.,Wei,Y.,Kuo,Y.C.,Wei,S.,Zhou,A.,Zou,Z.,Yehl,J.,Ranaghan,M.J.,Skepner,A.,Bittker,J.A.,et al.(2018).High-Throughput Screens To IdentifyAutophagy Inducers That Function by Disrupting Beclin 1 / Bcl-2 Binding.ACSChemical Biology 13,2247-2260.

[0147] Choi,M.E.(2020).Autophagy in Kidney Disease.Annual Review ofPhysiology 82,297-322.Cook,K.L., A.,Soto-Pantoja,D.R.,Clarke,P.A.G.,Cruz,M.I.,Zwart,A.,and Clarke,R.(2014).Hydroxychloroquine inhibits autophagy topotentiate antiestrogen responsiveness in ER+breast cancer.Clinical CancerResearch:An Official Journal of the American Association for Cancer Research20,3222-3232.

[0148] Deretic,V.(2021).Autophagy in inflammation,infection,andimmunometabolism.Immunity 54,437-453.

[0149] Dikic,I.,and Elazar,Z.(2018).Mechanism and medical implications ofmammalian autophagy.Nature Reviews.Molecular Cell Biology 19,349-364.

[0150] Eisenberg,T.,Abdellatif,M,Schroeder,S.,Primessnig,U.,Stekovic,S.,Pendl,T.,Harger,A.,Schipke,J.,Zimmerrnann,A.,Schmidt,A.,et al.(2016).Cardioprotection and lifespan extension by the natural polyaminespermidine.Nature Medicine 22,1428-1438.

[0151] Fabrizio,P.,Hoon,S.,Shamalnasab,M.,Galbani,A.,Wei,M.,Giaever,G.,Nislow,C.,and Longo,V.D.(2010).Genome-wide screen in Saccharomyces cerevisiaeidentifies vacuolar protein sorting,autophagy,biosynthetic,and tRNAmethylation genes involved in life span regulation.PLoS Genetics 6,1-14.

[0152] Fernández, F.,Bárcena,C.,Martinez-Garcia,G.G.,Tamargo-Gómez,I.,Suárez,M.F.,Pietrocola,F.,Castoldi,F.,Esteban,L.,Sierra-Filardi,E.,Boya,P.,etal.(2017).Autophagy couteracts weight gain,lipotoxicity and pancreaticβ-celldeath upon hypercaloric pro-diabetic regimens.Cell Death&Disease 8.

[0153] Fernández,, F.,Sebti,S.,Wei,Y.,Zou,Z.,Shi,M.,McMillan,KL.,He,C.,Ting,T.,Liu,Y.,Chiang,W.C.,et al.(2018).Disruption of the beclin 1-BCL2autophagy regulatory complex promotes longevity in mice.Nature 558,136-140.

[0154] Galluzzi,L.,Pietrocola,F.,Levine,B.,and Kroemer,G.(2014).Metaboliccontrol of autophagy.Cell 159,1263-1276.

[0155] Galluzzi,L.,Bravo-San Pedro,J.M.,Levine,B.,Green,D.R.,and Kroemer,G.(2017).Pharmacological modulation of autophagy:therapeutic potential andpersisting obstacles.Nature Reviews.Drug Discovery 16,487-511.

[0156] Galluzzi,L.,Yamazaki,T.,and Kroemer,G.(2018).Linking cellular stressresponses to systemic homeostasis.Nature Reviews.Molecular Cell Biology 19,731-745.

[0157] Grajeda-lglesias,C.,Durand,S.,Daillére,R.,Iribarren,K.,Lemaitre,F.,Derosa,L.,Aprahamian,F.,Bossut,N.,Nirmalathasan,N.,Madeo,F.,et al.(2021).Oraladministration of Akkermansia muciniphila elevates systemic antiaging andanticancer metabolites.Aging 13,6375-6405.

[0158] Hansen,M.,Rubinsztein,D.C.,and Walker,D.W.(2018).Autophagy as apromoter of longevity:insights from model organisms.Nature Reviews.MolecularCell Biology 19,579-593.

[0159] Haspel,J.,Shaik,R.S.,Ifedigbo,E.,Nakahira,K,Dolinay,T.,Englert,J.A.,and Choi,A.M.K(2011).Characterization of macroautophagic flux in vivo using aleupeptin-based assay.Autophagy 7,629-642.

[0160] Hazari,Y.,Bravo-San Pedro,J.M.,Hetz,C.,Galluzzi,L.,and Kroemer,G.(2020).Autophagy in hepatic adaptation to stress.Journal of Hepatology 72,183-196.

[0161] Joseph,A.,Moriceau,S.,Sica,V.,Anagnostopoulos,G.,Pol,J.,Martins,I.,Lafarge,A.,Maiuri,M.C.,Leboyer,M.,Loftus,J.,et al.(2020).Metabolic andpsychiatric effects of acyl coenzyme A binding protein(ACBP) / diazepam bindinginhibitor(DBI).Cell Death&Disease 11.

[0162] Joseph,A.,Chen,H.,Anagnostopoulos,G.,Montégut,L.,Lafarge,A., O.,Castedo,M.,Maiuri,M.C.,Clément,K.,Terrisse,S.,et al.(2021).Effects of acyl-coenzyme A binding protein(ACBP) / diazepam-binding inhibitor(DBI)on body massindex.Cell Death&Disease 12.

[0163] Kim,D.,Paggi,J.M.,Park,C.,Bennett,C.,and Salzberg,S.L.(2019).Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype.NatureBiotechnology 37,907-915.

[0164] Kim,S.N.,Lee,J.,Yang,H.S.,Cho,J.W.,Kwon,S.,Kim,Y.B.,Her,J.D.,Cho,K.H.,Song,C.W.,and Lee,K(2010).Dose-response Effects of Bleomycin onInflammation and Pulmonary Fibrosis in Mice.Toxicological Research 26,217.

[0165] Kitada,M.,and Koya,D.(2021).Autophagy in metabolic disease andageing.Nature Reviews.Endocrinology 17,647-661.

[0166] Klionsky,D.J.,Petroni,G.,Amaravadi,R.K,Baehrecke,E.H.,Ballabio,A.,Boya,P.,Bravo-San Pedro,J.M.,Cadwell,K.,Cecconi,F.,Choi,A.M.K.,et al.(2021).Autophagy in major human diseases.The EMBO Joumal 40.

[0167] Kroemer,G.,and Levine,B.(2008).Autophagic cell death:the story of amisnomer.Nature Reviews.Molecular Cell Biology 9,1004-1010.

[0168] Levine,B.,and Kroemer,G.(2019).Biological Functions of AutophagyGenes:A Disease Perspective.Cell 176,11-42.

[0169] Liang,W.,Menke,A.L.,Driessen,A.,Koek,G.H.,Lindeman,J.H.,Stoop,R.,Havekes,L.M.,Kleemann.,R.,and van den Hoek,A.M.(2014).Establishment of ageneral NAFLD scoring system for rodent models and comparison to human liverpathology.PloS One 9.

[0170] Lin,Z.,Wu,F.,Lin,S.,Pan,X,Jin,L.,Lu,T.,Shi,L.,Wang,Y.,Xu,A.,and Li,X(2014).Adiponectin protects against acetaminophen-induced mitochondrialdysfunction and acute liver injury by promoting autophagy in mice.Journal ofHepatology 61,825-831.

[0171] Loomis,W.F.,Behrens,M.M.,Williams,ME.,and Anjard,C.(2010).Pregnenolone sulfate and cortisol induce secretion of acyl-CoA-bindingprotein and its conversion into endozepines from astrocytes.The Journal ofBiological Chemistry 285,21359-21365.

[0172] López-Otín,C.,and Kroemer,G.(2021).Hallmarks of Health.Cell 184,33-63.

[0173] Love,MI.,Huber,W.,and Anders,S.(2014).Moderated estimation of foldchange and dispersion for RNA-seq data with DESeq2.Genome Biology 15.

[0174] Lu,Y.X.,Regan,J.C.,Eββer,J.,Drews,L.F.,Weinseis,T.,Stinn,J.,Hahn,O.,Miller,R.A., S.,and Partridge,L.(2021).A TORC 1-histone axis regulateschromatin organisation and non-canonical induction of autophagy to ameliorateageing.ELife 10.

[0175] Madeo,F.,Camona-Gutierrez,D.,Hofer,S.J.,and Kroemer,G.(2019).CaloricRestriction Mimetics against Age-Associated Disease:Targets,Mechanisms,andTherapeutic Potential.Cell Metabolism 29,592-610.

[0176] Meléndez,A.,Tallóczy,Z.,Seaman,M.,Eskelinen,E.L.,Hall,D.H.,andLevine,B.(2003).Autophagy genes are essential for dauer development and life-span extension in C.elegans.Science(New York,N.Y.)301,1387-1391.

[0177] Mizushima,N.,and Klionsky,D.J.(2007).Protein turnover via autophagy:implications for metabolism.Annual Review of Nutrition 27,19-40.

[0178] Mizushima,N.,Yamamoto,A,Matsui,M,Yoshimori,T.,and Ohsumi,Y.(2004).Invivo analysis of autophagy in response to nutrient starvation usingtransgenic mice expressing a fluorescent autophagosome marker.MolecularBiology of the Cell 15,1101-1111.

[0179] Montagner,A.,Polizzi,A.,Fouché,E.,Ducheix,S.,Lippi,Y.,Lasserre,F.,Barquissau,V.,Régnier,M.,Lukowicz,C.,Benhamed,F.,et al.(2016).Liver PPARα iscrucial for whole-body fatty acid homeostasis and is protective againstNAFLD.Gut 65,1202-1214.

[0180] Montégut,L.,Chen,H.,Bravo-San Pedro,J.M., O.,Martins,I.,andKroemer,G.(2022).Immunization of mice with the self-peptide ACBP coupled tokeyhole limpet hemocyanin.STAR Protocols3,101095.

[0181] Morishita,H.,and Mizushima,N.(2019).Diverse Cellular Roles ofAutophagy.Annual Review of Cell and Developmental Biology 35,453-475.

[0182] O.,Agra,N.,Brea Contreras,R.,Dominguez-Moreno,M.,García-Monzón,C.,Vargas-Castrillón,J.,Carnovale,CE,Boscá,L.,Casado,M.,Mayoral,R.,et al.(2016).Cyclooxygenase-2 expression in hepatocytes attenuates non-alcoholicsteatohepatitis and liver fibrosis in mice.Biochimica et Biophysica Acta-Molecular Basis of Disease 1862.

[0183] O.,Francés,DE,Casanova,N.,Fuertes-Agudo,M.,Cucarella,C.,Flores,JM,Vallejo-Cremades,MT,Olmedilla,L.,Pérez J., R.,et al.(2019).Protective Role of Hepatocyte Cyclooxygenase-2 Expression AgainstLiver Ischemia-Reperfusion Injury in Mice.Hepatology 70.

[0184] Gap junction dysfunction reduces acetaminophen hepatotoxicitywith impact on apoptotic signaling and connexin 43 protein induction in rat 38,280-286.

[0185] PloS One 12. Nakade, Y., Sakamoto, K., Yamauchi, T., Inoue, T., Kobayashi, Y., Yamamoto, T., Ishii, N., Ohashi, T., Sumida, Y., Ito, K., et al.

[0186] Neess ,D. ,Bek ,S. ,Engelsby ,H. ,Gallego ,SF NJ(2015).Long-chain acyl-CoA esters in metabolism and signaling:Role of acyl-CoA bindingproteins.Progress in Lipid Research59,1-25.

[0187] Neess,D.,Kruse,V.,Marcher,AB, MR,Vistisen,J., PM, Petersen, R., Brewer, JR, Ma, T., Colleluori, G., et al.(2021).Epidermal Acyl-CoA-binding protein is indispensable for systemic energy homeostasis.MolecularMetabolism 44 .

[0188] Powell,E.E.,Wong,V.W.S.,and Rinella,M.(2021).Non-alcoholic fattyliver disease.Lancet(London,England)397,2212-2224.

[0189] Pyo,J.O.,Yoo,S.M.,Ahn,H.H.,Nah,J.,Hong,S.H.,Kam,T.I.,Jung,S.,andJung,Y.K.(2013).Overexpression of Atg5 in mice activates autophagy andextends lifespan.Nature Communications 4.

[0190] Racanelli,A.C.,Choi,AM.K,and Choi,M.E(2020).Autophagy in chronic lungdisease.Progress in Molecular Biology and Translational Science 172,135-156.

[0191] Schlaepfer,I.R.,and Joshi,M.(2020).CPT1A-mediated Fat Oxidation,Mechanisms,and Therapeutic Potential.Endocrinology 16 I.

[0192] Schwartz,L.M.(2021).Autophagic Cell Death During Development-Ancientand Mysterious.Frontiers in Cell and Developmental Biology 9.

[0193] Sciarretta,S.,Maejima,Y.,Zablocki,D.,and Sadoshima,J.(2018a).The Roleof Autophagy in the Heart.Annual Review of Physiology 80,1-26.

[0194] Sciarretta, S.,Yee, D., Nagarajan, N., Bianchi, F., Saito, T., Valenti, V., Tong, M., Del Re, D., Vecchione, C., Schirone, L., et al MyocardialInfarction.Journal of the American College of Cardiology71,1999-2010.

[0195] Serviddio,G.,Giudetti,AM,Bellanti,F.,Priore,P.,Rollo,T.,Tamborra,R.,Siculella,L.,Vendemiale,G.,Altomare,E,and Gnoni,Gv(2011).Oxidation ofHepatic Carnitine Palmitoyl Transferase-I(CPT-I)Impairs Fatty Acid Beta-Oxidation in Rats Fed a Methionine-Choline Deficient Diet.PLoS ONE 6,24084.

[0196] Shamalnasab , M. , Dhaoui , M. , Thondamal , M. , Harvald , EB HIF-1-dependent regulation of lifespan in Caenorhabditis elegans by the acyl-CoA-binding protein MAA-1.Aging 9,1745-1769.

[0197] Sharma,P.,and Allison,J.P.(2015).Immune checkpoint targeting incancer therapy:toward combination strategies with curative potential.Cell161,205-214.

[0198] Shen,Y.,Malik,S.A.,Amir,M.,Kumar,P.,Cingolani,F.,Wen,J.,Liu,Y.,Zhao,E.,Farris,A.B.,Raeman,R.,et al.(2020).Decreased Hepatocyte Autophagy Leads toSynergistic IL-1βand TNF Mouse Liver Injury and Inflammation.Hepatology(Baltimore,Md.)72,595-608.

[0199] Shirakabe,A.,Fritzky,L.,Saito,T.,Zhai,P.,Miyamoto,S.,Gustafsson, B.,Kitsis,R.N.,and Sadoshima,J.(2016).Evaluating mitochondrial autophagy in themouse heart.Journal of Molecular and Cellular Cardiology 92,134-139.

[0200] Suzuki,S.,Toledo-Pereyra,L.H.,Rodriguez,F.J.,and Cejalvo,D.(1993).Neutrophil infiltration as an important factor in liver ischemia andreperfusion injury.Modulating effects of FK506 andcyclosporine.Transplantation 55,1265-1271.

[0201] Tag,C.G.,Sauer-Lehnen,S.,Weiskirchen,S.,Borkham-Kamphorst,E.,Tolba,R.H.,Tacke,F.,and Weiskirchen,R.(2015).Bile Duct Ligation in Mice:Inductionof Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis.JoVE(Journal of Visualized Experiments)96,e52438.

[0202] Tavernarakis,N.,Pasparaki,A.,Tasdemir,E.,Maiuri,M.C.,and Kroemer,G.(2008).The effects of p53 on whole organism longevity are mediated byautophagy.Autophagy 4,870-873.

[0203] Thomas,A.M.,Asnicar,F.,Kroemer,G.,and Segata,N.(2021).Genes EncodingMicrobial Acyl Coenzyme A Binding Protein / Diazepam-Binding InhibitorOrthologs Are Rare in the Human Gut Microbiome and Show No Links toObesity.Applied and Environmental Microbiology 87,1-11.

[0204] Tong,M.,Saito,T.,Zhai,P.,Oka,S.I.,Mizushima,W.,Nakamura,M.,Ikeda,S.,Shirakabe,A.,and Sadoshima,J.(2019).Mitophagy Is Essential for MaintainingCardiac Function During High Fat Diet-Induced DiabeticCardiomyopathy.Circulation Research 124,1360-1371.

[0205] Venkatesh,S.,Li,M.,Saito,T.,Tong,M.,Rashed,E.,Mareedu,S.,Zhai,P.,Báárcena,C.,López-Otín,C.,Yehia,G.,et al.(2019).Mitochondrial LonP1 protectscardiomyocytes from ischemia / reperfusion injury in vivo.Journal of Molecularand Cellular Cardiology 128,38-50.

[0206] Wang,J.,Vasaikar,S.,Shi,Z.,Greer,M.,and Zhang,B.(2017).WebGestalt2017:a more comprehensive,powerful,flexible and interactive gene setenrichment analysis toolkit.Nucleic Acids Research 45,W130-W137.

[0207] Wulff,P.,Goetz,T., E.,Linden,A.M.,Renzi,M.,Swinny,J.D.,Vekovischeva,O.Y.,Sieghart,W.,Somogyi,P.,Korpi,E.R.,et al.(2007).From synapseto behavior:rapid modulation of defined neuronal types with engineered GABAAreceptors.Nature Neuroscience 10,923-929.

[0208] Xiao,S.,and Chye,M.L(2010).The Arabidopsis thaliana ACBP3 regulatesleaf senescence by modulating phospholipid metabolism and ATG8stability.Autophagy 6.

[0209] Zhao,J.,Park,S.,Kim,J.W.,Qi,J.,Zhou,Z.,Lim,C.W.,and Kim,B.(2020).Nicotine attenuates concanavalin A-induced liver injury in mice byregulating the α7-nicotinic acetylcholine receptor in Kupffercells.International Immunopharmacology 78.

Claims

1. A composition for treating tissue damage caused by chemical injury, physical injury or ischemic injury in an organ of a subject, the composition comprising an agent that inhibits the activity or expression of a diazepam binding inhibitor (DBI), wherein the amount of the agent is sufficient to treat tissue damage caused by chemical injury, physical injury or ischemic injury in the organ of the subject when administered to the subject.

2. The composition of claim 1, wherein the agent inhibits the activity of extracellular DBI.

3. The composition of claim 1, for use in treating tissue damage caused by chemical injury induced by a poison selected from the group consisting of alcohol, 2,2′,4,4′,5,5′-hexachlorobiphenyl (PCB-153), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), 2-bromoethylamine (BEA), 3-methylcholanthrene, 4-aminophenol (PAP), acetaminophen, doxorubicin, allyl alcohol, amiodarone, amphotericin B, Aroclor 1254, Aroclor1260, arsenic, aspirin, astemizole, benzene, cadmium, carbamazepine, carbon tetrachloride (CCl4), ciprofibrate (cipro), clofibrate, cobalt chloride, kovastatin, cyclosporine A, diethylnitramine, dimethylformamide, dimethylhydrazine (DMH), diquat, ethosuximide, etoposide, famotidine, fluconazole, gemfibrozil, ganciclovir, hexachloro-1,3-butadiene (HCBD), HIV protease inhibitors, hydrazine, indomethacin, ketoconazole, lead acetate (PbAc), lipopolysaccharide (LPS), mercury (II) chloride (HgCl2), methanol, methapyrile, methotrexate, metronidazole, miconazole, monocrotaline, nitric oxide, ondansetron, pentamidine, phenobarbital, phenylhydrazine (phe nylhyrzn), phenytoin, pravastatin, cisapride, puromycin aminonucleoside (PAN), quinolones, simvastatin, sodium fluoride (NaF), statins, thioacetamide, tocainidine, tricyclic antidepressants, troglitazone, tumor necrosis factor alpha (TNFα), uranyl nitrate, valproic acid, vincristine, Wy-16,463, zidovudine (AZT), alpha-naphthyl isothiocyanate (ANIT), beta-naphthoflavone (BNF), asbestos, radon, cigarette smoke, glue, dioxins, nickel, arsenic, mercury, cement (chromium), polychlorinated biphenyls (PCB), carbon tetrachloride, methylene chloride, vinyl chloride, mercury, chlorinated hydrocarbon solvents, carbon disulfide, cadmium, ozone, tobacco smoke, nitrates, methylene chloride, vinyl dibromide, and polychlorinated biphenyls.

4. The composition of claim 1, for use in treating tissue damage caused by chemotherapeutic agents.

5. The composition of claim 4, wherein the chemotherapeutic agent is an anthracycline selected from the group consisting of daunorubicin, doxorubicin, epirubicin, famorubicin, idarubicin, mitoxantrone, pixantrone; and pharmaceutically acceptable salts thereof.

6. The composition of claim 1, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to treat acetaminophen-induced hepatotoxicity, amiodarone-induced pulmonary toxicity, doxorubicin-induced cardiotoxicity, cadmium chloride-induced nephrotoxicity, dimethylnitrosamine-induced splenoretoxicity, and O-ethyl-S,S-dipropyl dithiophosphate (MOCAP)-induced neurotoxicity.

7. The composition of claim 1, for use in treating ischemic injury.

8. The composition of claim 7, wherein the ischemic injury is myocardial infarction.

9. The composition of claim 1, wherein the subject suffers from ischemia-reperfusion injury.

10. The composition of claim 1, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to reduce or delay the progression of acute kidney injury (AKI) to chronic kidney disease (CKD).

11. A composition for reducing the severity of injury to an isolated organ, the composition comprising an agent that inhibits the activity or expression of diazepam binding inhibitor (DBI), the amount of the agent being sufficient to reduce the severity of injury to the isolated organ when in contact with the isolated organ.

12. The composition of claim 11, wherein the isolated organ is a transplantable organ.

13. A composition for reducing fibrosis associated with organ damage in a subject in need thereof, the composition comprising an agent that inhibits the activity or expression of a diazepam binding inhibitor (DBI), wherein the amount of the agent is sufficient to reduce the amount of fibrosis associated with the organ damage in the organ after the administration, compared to the amount of fibrosis in the organ of the subject in the absence of the administration.

14. The composition of claim 13, wherein the agent inhibits the activity of extracellular DBI.

15. The composition of claim 14, wherein the fibrosis occurs in an organ selected from the group consisting of skin, heart, liver, lung, and kidney.

16. The composition of claim 15, wherein the organ is the liver.

17. The composition of claim 16, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to reduce the level of the transaminase in the subject upon administration as compared to the level of the transaminase in the subject prior to administration.

18. The composition of claim 17, wherein the transaminase is aspartate aminotransferase (AST) or alanine aminotransferase (ALT).

19. The composition of claim 16, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to reduce the fibrosis score by at least 1 / 3 relative to the fibrosis score before the administration.

20. The composition of claim 16, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to reduce the subject's hydroxyproline level upon administration as compared to the subject's hydroxyproline level prior to administration.

21. The composition of any one of claims 16-20, wherein the fibrosis is associated with non-alcoholic fatty liver disease (NAFLD).

22. The composition of claim 21, wherein the agent that inhibits the activity or expression of DBI is present in an amount sufficient to reduce the NAFLD score of the subject upon administration relative to the NAFLD score prior to administration.

23. The composition of any one of claims 1-22, wherein the agent that inhibits the activity of DBI is an antibody or aptamer against DBI.

24. The composition of claim 23, wherein the antibody is directed against a polypeptide fragment of DBI, the polypeptide fragment comprising the amino acid sequence from position 43 to position 50 of SEQ ID NO:

1.

25. The composition of claim 23, wherein the antibody is a monoclonal chimeric antibody, a monoclonal humanized antibody, or a monoclonal human antibody.

26. The composition of any one of claims 1-22, wherein the agent that inhibits the expression of DBI is an expression inhibitor selected from the group consisting of siRNA, endonuclease, antisense oligonucleotide and ribozyme.

27. The composition of any one of claims 1-22, wherein the agent that inhibits the activity of DBI is in the form of a vaccine composition suitable for eliciting neutralizing autoantibodies against DBI when administered to the subject.

28. A composition as described in claim 27, wherein the vaccine composition comprises an antigen, the antigen comprising i) an amino acid sequence having at least 80% identity with SEQ ID NO:1, ii) an amino acid sequence having at least 80% identity with the amino acid sequence from position 17 to position 50 in SEQ ID NO:1, iii) an amino acid sequence having at least 80% identity with the amino acid sequence from position 33 to position 50 in SEQ ID NO:1, or iv) an amino acid sequence having at least 80% identity with the amino acid sequence from position 43 to position 50 in SEQ ID NO:

1.

29. A method for treating tissue damage caused by chemical, physical, or ischemic injury in the liver of a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity or expression of a diazepam binding inhibitor (DBI), wherein the administration is sufficient to treat tissue damage caused by chemical, physical, or ischemic injury in the liver of the subject.

30. A method for treating tissue damage caused by chemical, physical, or ischemic injury in the heart of a subject in need thereof, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity or expression of a diazepam binding inhibitor (DBI), wherein the administration is sufficient to treat tissue damage caused by chemical, physical, or ischemic injury in the heart of the subject.

31. A composition comprising an agent that inhibits the activity or expression of diazepam binding inhibitor (DBI), wherein the amount of the agent, when administered to a subject, is sufficient to treat tissue damage caused by chemical injury, physical injury, or ischemic injury in the liver of the subject.

32. A composition comprising an agent that inhibits the activity or expression of diazepam binding inhibitor (DBI) in an amount sufficient to treat tissue damage caused by chemical injury, physical injury, or ischemic injury in the heart of a subject when administered to the subject.

33. A composition comprising an agent that inhibits the activity or expression of diazepam binding inhibitor (DBI), in an amount sufficient to reduce the amount of fibrosis associated with organ damage in a subject following administration as compared to the amount of fibrosis in the absence of administration.

Citation Information

Patent Citations

  • Polymeric ultraviolet light stabilisers containing hindered alkyl amines and polymer compositions containing them

    EP0002022A1

  • Recombinant immunoglobin preparations

    US4816567A

  • Ransgenic non-human animals for producing heterologous antibodies

    US5545806A

  • Production of antibodies from transgenic animals

    US5545807A

  • Transgenic mice depleted in a mature lymphocytic cell-type

    US5591669A